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“Where nature finishes producing its own species,  
man begins, using natural things and with the help 
of this nature, to create an infinity of species.”                        
                                          Leonardo da Vinci 
 
“True wisdom comes to each of us when we realize how little 
we understand about life, ourselves, and the world around us.” 
Socrates (BC 469 – 399) 
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ABSTRACT 
Mesoporous silica nanoparticles (MSNs) are a highly promising platform for 
intracellular controlled release of drugs and biomolecules. Despite that the application of 
MSNs in the field of intracellular drug delivery is still at its infancy very exciting 
breakthroughs have been achieved in the last years. A general review of the most recent 
progress in this area of research is presented, including a description of the latest findings on 
the pathways of entry into live mammalian cells together with the intracellular trafficking, a 
summary on the contribution of MSNs to the development of site-specific drug delivery 
systems, a report on the biocompatibility of this material in vitro and in vivo, and a discussion 
on the most recent breakthroughs in the synthesis and application of stimuli-responsive 
mesoporous silica-based delivery vehicles. 
A gold nanoparticles (AuNPs)-capped MSNs-based intracellular photoinduced drug 
delivery system (PR-AuNPs-MSNs) for the controlled release of anticancer drug inside of 
human fibroblast and liver cells was synthesized and characterized. We found that the 
mesoporous channels of MSNs could be efficiently capped by the photoresponsive AuNPs 
without leaking the toxic drug, paclitaxel, inside of human cells. Furthermore, we 
demonstrated that the cargo-release property of this PR-AuNPs-MSNs system could be easily 
photo-controlled under mild and biocompatible conditions in vitro. 
In collaboration with Renato Mortera (a visiting student from Italy), a MSNs based 
intracellular delivery system for controlled release of cell membrane impermeable cysteine 
was developed. A large amount of cysteine molecules were covalently attached to the silica 
surface of MSNs through cleavable disulfide linkers. These cysteine-containing nanoparticles 
were efficiently endocytosed by human cervical cancer cells HeLa. These materials exhibit 
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450 times higher cell growth inhibition capability than that of the conventional N-
acetylcysteine prodrug.  
The ability to functionalize the surface of the MSNs with organic groups was used as 
a way to incorporate functional molecules that can interact with intracellular structures. A 
series of oligonucleotides intercalating (propidium) derivative functionalized MSNs (PAP-
LP-MSNs and AP-PAP-MSNs) materials were synthesized. We selectively decorated the 
exterior particle surface of PAP-LP-MSN and the interior pore surface of AP-PAP-MSN with 
the oligonucleotide intercalating functionality. We observed that these materials are 
internalized by HeLa cells despite that the propidium group is known by its cell membrane 
impermeable properties.  By confocal microscopy and flow cytometry, we demonstrated that 
indeed PAP-LP-MSNs were able to bind to cytoplasmic oligonucleotides; such as messenger 
RNA, resulting in severe cell growth inhibition. In contrast, the cytotoxicity of AP-PAP-
MSN, where the same oligonucleotide intercalating molecules were anchored inside the 
pores, was significantly lowered upon the endocytosis by HeLa cells. The results obtained 
prove that the biocompatibility and cell membrane trafficking properties of MSNs could be 
modified by selective functionalization of the two different surfaces (exterior particle and 
interior pore surfaces) and morphology control of MSNs. 
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CHAPTER 1. DISSERTATION ORGANIZATION 
 This thesis is organized in six chapters. Chapter 1 describes an overview of this 
dissertation. Chapters 2 to 5 are journal articles; Chapter 3 and 4 have already been 
published, Chapter 2 and 5 have been submitted for publication, and Chapter 6 describes the 
significance and future work of the research done in this dissertation. 
Chapter 2 describes a general introduction about the application of MSNs for 
intracellular drug delivery. Some of the most important topics in this area are addressed in 
this literature review. The aim of this chapter is to describe the latest breakthroughs in the 
field and to put them together in the context of the development of MSNs as a promising 
platform for drug delivery. 
The ability to release drugs in a time- and site-controlled fashion is one of the most 
desired features for a drug delivery carrier. Chapter 3 is a study on the synthesis and 
application of a gold nanoparticles capped MSNs-based drug delivery vehicle. The novel 
feature of this system is that the release of drugs is controlled by an external trigger 
(irradiation under mild conditions). The application of this carrier was successfully 
demonstrated in human cells.   
Some of the outstanding features that make MSNs a unique material for drug delivery 
are their high surface area and efficient internalization by mammalian cells. Chapter 4 
describes the synthesis of a cysteine functionalized MSNs material. The intracellular release 
of cell impermeable cysteine was controlled by the reducing environment. The high loading 
and efficient release of cysteine from MSNs was demonstrated against the conventional N-
acetylcysteine prodrug. 
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Different inorganic nanoparticles are being investigated for their biomedical and 
biological applications. However, MSN is one of the few nanomaterials that have the 
structural feature of possessing two different surfaces. Chapter 5 involves the description of 
the development of a series of intercalator-functionalized MSNs that bind specifically to 
oligonucleotides. The intercalating group (phenanthridium molecule) was selectively grafted 
on the exterior particle surface and interior pore surface of MSNs. The effect of the 
localization of the phenanthridium group on the biocompatibility and cell membrane 
trafficking properties of these materials are reported. 
Finally in Chapter 6 describes a general conclusion for this research and gives future 
directions for the continuous development of this field. 
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CHAPTER 2. MESOPOROUS SILICA NANOPARTICLES FOR INTRACELLULAR 
CONTROLLED DRUG DELIVERY 
 
A manuscript submitted to Small 
Juan L. Vivero-Escoto, Igor I. Slowing, Brian G. Trewyn and Victor S.-Y. Lin 
 
Abstract 
The application of nanotechnology in the field of drug delivery has attracted a lot of 
attention in the last decades. Recently, the development of new delivery vehicles based on 
inorganic nanomaterials has brought new possibilities to this area of research. In the case of 
mesoporous silica nanoparticles recent breakthroughs have demonstrated its high potential in 
this field. The ability to functionalize the surface of this silica-based nanocarrier with stimuli-
responsive nanoparticles that work as gatekeepers, the binding of bio-functional moieties, 
and its high surface area are just some of the outstanding features that make this material a 
serious candidate to become a drug delivery platform. This review focuses on the most recent 
progress in the application of mesoporous silica nanoparticles for intracellular drug delivery. 
The latest research on the pathways of entry into mammalian cells together with intracellular 
trafficking are described. One of the main areas of interest in the last years in this field is the 
development of site-specific drug delivery vehicles; the contribution of mesoporous silica 
nanoparticles toward this topic is also summarized. In addition, the current research on the 
biocompatibility of this material in vitro and in vivo is discussed. Finally, the latest 
breakthroughs in intracellular controlled drug release using stimuli-responsive mesoporous 
silica-based systems are described. 
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1. Introduction 
The design of site-specific stimuli-responsive controlled drug delivery systems (DDS) 
is of utmost importance for the continued advancement of biomedical, personal health care, 
and pharmaceutical industry. DDS that could manipulate the biological profiles such as 
pharmacokinetics, pharmacodynamics, therapeutic index, biodistribution, and tissue uptake 
of therapeutic agents are of major interest of researchers worldwide. One of the key 
challenges of such DDS is to have the ability of transporting an effective amount of drug 
with fewer acute and chronic side effects than those of the current treatment methods, such as 
chemotherapy.[1-3] Obviously, to successfully achieve these goals several prerequisites need 
to be incorporated into such delivery carriers. Some of the most important prerequisites for 
designing these systems are outlined below: 
 The vehicle should be biocompatible 
 High loading and protection of the desired guest molecule 
 Zero premature release before reaching its target 
 Efficient cellular uptake 
 Effective endosomal escape 
 Controllable rate of release to achieve an effective local concentration 
 Cell and tissue targeting 
In the past decades different strategies have been developed to design drug delivery 
materials to accomplish the aforementioned prerequisites. For instance, several drug delivery 
nanocarriers based on organic platforms such as liposomes, polymers, and dendrimers have 
been used as “smart” systems that can release therapeutic agents under physiological 
conditions.[2, 4-6] Moreover, recent discoveries based on inorganic nanoparticles and carbon 
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nanotubes have opened up new and exciting possibilities in this field.[7-9] Nanoparticles such 
as gold,[10] semiconductor nano-crystals,[11] superparamagnetic nanoparticles,[12] silicon-,[13] 
and silica-based nanosystems have been extensively studied as promising candidates for drug 
delivery.[14]  
Among these inorganic-based materials, mesoporous silica nanoparticles (MSNs) 
have attracted much research attention for their potential application in the fields of 
biotechnology and biomedicine. MSNs are solid materials, which contain hundreds of empty 
channels (mesopores) arranged in a honeycomb-like porous structure (Figure 1). In contrast 
to the low biocompatibility of other amorphous silica materials, recent studies have shown 
that MSNs exhibit superior biocompatibility at concentrations adequate for pharmacological 
applications.[15, 16] These silica-based nanoparticles also offer several unique and 
advantageous structural properties, such as high surface area (> 700 m2/g), pore volume (> 1 
cm3/g), stable mesostructure, tunable pore diameter (2-10 nm), two functional surfaces 
(exterior particle and interior pore surfaces), and modifiable morphology (controllable 
particle sizes and shapes). For instance, their high surface area and pore volume allows for 
high drug loading. The tunable diffusional release of drug molecules from the highly ordered 
mesoporous structure gives rise to a biogenic local concentration at the targeted area, which 
reduces the overall dosage and prevents any acute or chronic complications. In addition, 
MSNs offer the ability of effectively protect the precious pharmaceutical cargos, such as 
drugs, imaging agents, enzymes, and oligonucleotides from premature release and the 
undesired degradation in harsh environments, such as stomach and intestine, before reaching 
the designated target. In contrast to other DDS, the guest molecules can be loaded to MSNs 
without adsorbing the solvent molecules that are often toxic for healthy cells.[17] 
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Another advantage of MSNs is the possibility to be further functionalized adding 
features either onto their external surface or inside the nano-channels.[18, 19] These features 
may include: functionalization with stimuli-responsive tethers that could be attached to 
nanoparticles (gold, quantum dots, and iron oxide). These nanoparticles could work as 
gatekeepers, which once the MSNs-based vehicle is in the designated site they can be 
removed by either an intracellular or external trigger such as change in pH, reducing 
environment, enzymatic activity, light, electromagnetic field, or ultrasound. In addition, 
MSNs surface can be engineered with cell specific moieties such as organic molecules, 
peptides or antibodies to achieve cell type or tissue specificity. Moreover, optical and 
magnetic contrast agents can be introduced to develop multi-purpose DDS. Figure 1 
illustrates more features that could be added to MSNs to develop a highly promising drug 
delivery platform. As one can conclude from the above mentioned features, MSN has not 
only potential for cancer treatment but maybe also for metabolic diseases, autoimmune 
diseases, and gene therapy.[20] 
2. Synthesis of mesoporous silica nanoparticles 
The synthesis of structurally ordered (MCM-type) mesoporous silica materials was 
first reported by scientists of Mobil Company in 1992.[21-23] The methodology was based on 
the condensation of silica precursors (i.e, sodium silicate, tetramethylammonium silicate, or 
tetraethyl orthosilicate) in presence of structure-directing agents (quaternary ammonium 
cationic surfactants) under hydrothermal and basic conditions. The scope of this micelle-
templated approach was extended by a number of variations leading to a wide variety of 
mesoporous silica materials, such as SBA-,[24] MSU-,[25] and FSM-types of mesoporous 
silica.[26, 27] Some of the novel features of these silica-based materials are unique porous 
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structure, tunable pore size, high thermal and hydrolytic stability, narrow pore size 
distribution, high surface area and large pore volume. However, the large size (above micron 
in diameter) and the irregularity in particle shape of these mesoporous silica particles had 
prevented the applications of these materials in areas such as separation (chromatography), 
biotechnology, and medicine (Figure 2).[28, 29] For this reason, novel synthetic strategies have 
been developed for controlling the structural (size and shape) and chemical properties of 
these silica-based materials.  
2.1 Control of structural properties (size and shape) 
The capability of tuning the structural features of MCM-type materials has a direct 
outcome in regulating the mass-transport properties of guest molecules and improving its 
biocompatibility as has been demonstrated by our group and others.[30-32] Different methods 
for tuning the structural properties of MSN have been developed based on the synergy 
between the Stöber process and the micelle-templated approach. For instance, Unger and co-
workers,[33] reported the shape-, and size-control of MCM-type mesoporous silica particles 
using the above strategy. They modified the Stöber process using a cationic surfactant as 
structure-directing agent. MSNs with MCM-41 type structure, spherical shape, and 
submicrometer-size (400-1100 nm) were obtained. The synthetic conditions such as pH and 
temperature can also affect the final properties of the resulting MSN material. For example, 
Cai and co-workers tuned the morphology of MSNs simply by selecting different pH-
adjusting agents.[34] This procedure yielded hexagonally ordered nanospheres (roughly 100 
nm in diameter) and nanorods (700-1000 nm in length, and 300-500 nm in width). In 
addition, Mou and co-workers,[35, 36] developed a pH-controlled method. The synthesis was 
carried out through a fast transfer from the original acid solution to basic media modifying 
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the kinetics of silica condensation. This method afforded well ordered type MCM-41 
nanorods and disordered nanospheres.  
On the other hand, Lin and co-workers have developed different strategies based on 
the co-condensation method for controlling the morphology of MSNs. One of the advantages 
of this process is that at the same time organic functional groups can be incorporated in the 
MSN.[37] Therefore, in addition to manipulate the shape of MSNs, this procedure also affords 
multi-functionalized materials. In this method different parameters have to be considered; 
such as, concentration, molecular size, and hydrophilicity/hydrophobicity of the 
organoalkoxysilanes (OAS) precursors. By tuning these parameters, we obtained 
nanoparticles with different shapes ranging from spherical, twisted columns, rod-shape, to 
tubular particles. All materials synthesized by this methodology showed a high surface area 
(> 600 m2/g), narrow pore size distribution (2.0-2.9 nm), and different mesoporous structures 
as summarized in Table 1. The working principle of this method is based on the 
hydrophilic/hydrophobic interaction between the OAS precursors and the CTAB surfactant 
micelle. To further gain structural control of MSNs by this methodology, we studied the 
effect of tuning the concentrations of OAS introduced in the synthesis of these materials.[30] 
For instance, in the case of using 3-[2-(2-
aminoethylamino)ethylamino]propyltrimethoxysilane (AEP-TMS) and 3-cyanopropyl 
trimethoxysilane (CP-TMS) mixture, particles with different sizes ranging from 3 µm to less 
than 500 nm were obtained. The different particle shapes obtained from this procedure varied 
from spherical to rods. Moreover, we demonstrated that the nanoparticle shape of these 
materials could be tuned and controlled by the hydrophilicity of OAS (AEP-TMS) groups.  
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Another strategy developed by our group to fine-tune the morphology of MSNs was 
the use of room-temperature ionic liquids (RTILs) as structure-directing agents.[38] 
Interestingly, the MSNs obtained through this method showed various particle shapes such as 
spheres, ellipsoids, rods, and tubes. We also obtained different mesoporous structures, such 
as hexagonal, rotational moiré type, and wormhole-like (Table 2). It is noteworthy to mention 
that in contrast to Tatsumi’s material,[39] the rotational moiré pattern of mesoporous obtained 
in this report was based on an achiral surfactant. In addition to these achievements, we also 
published a report on the synthesis of large pore MSNs (3-6 nm) by using a pore expanding-
agent (mesitylene).[40] The synthesis of this large pore MSNs was carried out to achieve the 
goal of releasing proteins (i.e. cytochrome c) inside mammalian cells. 
From the exciting results aforementioned we can conclude that it is possible to synthesize 
MSNs with the following unique features:  
 High surface area and large pore volume 
 Chemical and mechanical stability 
 Unique mesoporous structure 
 Narrow and tunable pore size 
 Well-define particle shape 
 Monodisperse particles 
 Tunable particle size 
2.2 Control of surface functionalization 
The capability of developing methods for controlling the degree of organic 
functionalization in MSNs is important in order to fine-tune its chemical properties. In this 
respect, one of the interesting advantages of MSNs is the fact that this material has two 
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functional surfaces; external (outside surface of the nanoparticles) and internal 
(nanochannels). The ability of selectively and efficiently functionalizing both surfaces is 
crucial for fine tuning the chemical and physical performance of MSN. Generally, two well-
established methods for the functionalization of MSNs materials have been applied: co-
condensation, and grafting.[41, 42] 
The co-condensation method has the advantages of homogeneous surface coverage in 
one-pot synthesis, better control over the amount of OAS groups incorporated in the MSNs, 
and the possibility of using a wide variety of organo-functional groups.[41] However, this 
method is not useful to functionalize the external surface of MSNs and there is a limitation in 
the amount of OAS groups incorporated to the material without compromising the 
mesostructure. To overcome these drawbacks some novel approaches have been reported in 
the literature.[43] For instance, our group used the co-condensation method to functionalize 
the MSNs with a wide variety of OAS groups (Table 1).[37] OAS with different molecular 
sizes, hydrophobic/hydrophilic properties, and concentrations were successfully incorporated 
into the MSNs nanochannels. The co-condensation of two different OAS groups was also 
carried out,[30] which opened the pathway for the synthesis of more sophisticated MSNs for 
catalysis and biosensors applications. Besides our group, Mann and co-workers have also 
used the co-condensation strategy to functionalized MSNs through a controlled quenching 
procedure.[44] 
On the other hand, the grafting procedure yields hydrothermally stable MSNs, and 
can selectively functionalize the exterior surface of MSNs materials.[42] This method also 
presents its own drawbacks, such as heterogeneous surface coverage and the fact that OAS 
groups tend to be grafted in the opening of the mesoporous blocking the interior of the 
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channels. Different factors can be involved in the efficient performance of the grafting 
method such as the type of solvent used for the reaction, temperature, type of OAS precursor, 
and reaction time. Asefa and co-workers have studied the influence of the polarity and 
dielectric constant of different solvents in the grafting method.[45] Three main properties were 
affected by the solvent: concentration of grafted groups, degree of site-isolation, and catalytic 
properties. The researchers found that polar-protic solvents resulted in lower concentrations 
of grafted groups, higher site-isolated organic groups, and more efficient catalytic properties. 
On the contrary, dipolar-aprotic and nonpolar solvents resulted in larger concentrations of 
grafted groups, more densely populated organic groups, and poor to efficient catalytic 
properties. 
The combination of both, the grafting and co-condensation method, can afford the 
selective functionalization of the exterior and/or interior surface of MSNs. The clever use of 
this combination has resulted in nanodevices with outstanding properties. For instance, our 
group published a report on the internal surface functionalization of MSNs with o-phtalic 
hemithiacetal (OPTA) group using the co-condensation method, and later the external surface 
of this MSNs material was functionalized with poly-(lactic acid) via the grafting method 
(Figure 3).[46] This nanodevice was used for the selective sensing of amino-containing 
neurotransmitters. In this case, the poly-(lactic acid) polymer coated in the exterior of MSNs 
has the role of gatekeeper to selectively allow the diffusion of certain neurotransmitters. The 
OPTA group reacted with the neurotransmitters when they reached the interior of the MSN. 
This reaction affords a fluorescent product that is the principle for detecting the 
neurotransmitters. Recently, we used a similar approach to selectively functionalize MSNs 
with poly(N-isopropylacrylamide) polymer (PNiPAm) on its exterior surface. This PNiPAm-
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coated MSNs exhibited interesting water solubility behavior which is controlled by the 
critical solution temperature of the polymer.[47] 
 
3. Intracellular uptake of mesoporous silica nanoparticles 
The most important barrier to overcome for intracellular drug delivery carriers is the 
cell membrane. MSNs uptake through mammalian cells can be challenging due to the large 
variety of intracellular transport mechanisms. Thorough understanding of the pathways for 
the cellular internalization of MSNs is a central challenge for many of its applications in 
biotechnology and biomedicine. There are a wide variety of pathways in mammalian cells for 
internalization of external material, and more are been discovered every year, but in general 
we can divide these mechanisms in two categories: phagocytosis, and pinocytosis 
(macropinocytosis and endocytosis) (Figure 4).[48, 49] Depending on the size of the particles to 
be engulfed the cells can use any of these internalization processes. Specialized cells such as 
macrophages use phagocytosis to engulf micro-size particles (> 1µm). On the other hand, the 
cellular uptake of small particles (<200-300 nm) such as MSNs, polymers, quantum dots, or 
carbon nanotubes is found to involve endocytosis for the majority of cases.[1] The process of 
endocytosis is mediated by several mechanisms that can transport the MSNs to different 
locations inside of the cytoplasm. Some of these endocytic routes are: clathrin-, and caveolin-
dependent, receptor-mediated, and clathrin-, and caveolin-independent endocytosis (Figure 
2). Endocytosis is a very complex process that consists of the selection at the cell surface, 
invagination and pinching-off, and finally tethering the just formed vesicles to the next stop 
in the intracellular trafficking journey.[48-50] So far, there is not “rule of thumb” to predict 
which endocytic pathway bare or functionalized MSNs follow for intracellular uptake. The 
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understanding and control of its internalization pathways is of utmost importance in its 
development as drug delivery platform.  
Previous reports on the intracellular uptake of silica-coated nanoparticles showed that 
it was possible to internalize these materials through endocytic pathways.[51, 52] However, in 
the case of MSNs none reports were found that demonstrated its intracellular uptake until we 
published our work on the synthesis and application of dendrimer-capped MSNs (PAMAM-
MSNs) for intracellular drug/gene delivery in 2004. Using transmission electron microscopy 
(TEM) we demonstrated the successful uptake of PAMAM-coated MSNs material in Chinese 
hamster ovarian (CHO) cells.[53] We observed that PAMAM-MSNs were localized nearby to 
subcellular organelles such as mitochondria and Golgi, as a clear demonstration of its 
successful uptake by mammalian cells. Later on, using a fluorescein isothiocyanate labeled 
MSNs (FITC-MSNs) material, flow cytometry, and confocal microscopy we were able to 
corroborate the internalization of MSNs inside cervical cancer cells (HeLa).[31] Moreover, we 
found that the uptake of FITC-MSNs is concentration dependent and follows a typical 
sigmoidal behavior of dose-response endocytosis. We further investigated the possible 
mechanisms for the endocytic trafficking of MSNs testing the cellular uptake of this material 
in presence of specific endocytic trafficking inhibitors. We found that the uptake of FITC-
MSNs is through a clathrin-dependent endocytosis mechanism (Table 3). Y. Hung, and 
coworkers also reported the efficient uptake of FITC-MSNs materials by 3T3-L1 fibroblast 
cells.[32] Moreover in a complementary report, Y.-C. Chen, and coworkers found that the 
internalization of FITC-MSN is concentration-, time-, and cell-dependent.[54] In this report 
the authors used human mesenchymal stem cells (hMSCs) and 3T3-L1 fibroblasts to 
demonstrate that the internalization of FITC-MSNs is mediated by a clathrin-dependent 
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endocytosis process. Recently, Zink and co-workers studied the energy-dependence of the 
cellular uptake of MSNs. By incubating the cells with MSNs at different temperatures, they 
found that the uptake of MSNs is higher at 37 °C than at 4 °C. This finding demonstrated that 
the uptake of MSNs is driven by an energy-dependent process confirming previous 
reports.[55] 
3.1 Effect of surface functionalization on the endocytic pathway 
The cell membrane is a very complex system that consists mainly of lipids, proteins, 
cholesterol, and receptors. One of its features is the highly negative charge on its 
surroundings. It is well established that either the charge of the nanocarrier or attaching cell 
membrane receptors can affect the endocytic trafficking in mammalian cells.[56] Considering 
these properties we were interested to investigate the charge effect on the uptake of MSNs by 
HeLa cells.[31] Four different MSNs materials were synthesized, tuning the surface charge 
based on either amino or guanidine functionalities; besides FITC-labeled MSNs was used as 
the control material, the carrier with the most negative charge. We found, as was expected, a 
trend in the internalization of the materials related with the surface charge. The ED50 values 
for these materials increased with the increase in the negative value of their surface charge. 
Interestingly, we also found that these materials did not follow the same endocytic pathway. 
Some of them were endocytosed through clathrin-mediated endocytosis (FITC-MSNs), and 
others through caveolin-mediated endocytosis (Table 3). Recently, Huang, D.-M., Mou, C.-
Y., and coworkers reported on the effect of the surface charge on the cellular uptake of 
MSNs in hMSCs and 3T3-L1 cells.[54] They found a correlation between the positive charge 
of MSNs and its internalization in 3T3-L1 cells. Interestingly, this correlation was not 
observed in hMSCs cells as an indication that the surface charge effect could also be cell type 
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dependent. Two inhibitors, phenylarsine oxide (PAO) and cytochalasin D (Cyt D) were used 
to investigate the endocytic pathways of these materials. The authors found that the 
endocytosis was carried through a clathrin- and an actin-dependent process. 
As part of our research on the effect of surface functionalization of MSNs on its 
internalization by HeLa cells, we also explored the possibility of modifying the MSNs 
surface with a receptor group (folic acid). We found a highly efficient endocytosis of this 
folic acid functionalized-MSNs (FA-MSNs) by HeLa cells.[31] Through a receptor 
competition experiment, we were able to prove that the endocytic mechanism of FA-MSNs is 
mediated by folic acid receptors. Further developments related with target specific systems 
based on MSNs will be described below. 
3.2 Effect of MSNs size and shape on the endocytic pathway 
Since the first applications of nanotechnology to intracellular gene/drug delivery, the 
researchers were aware of the possible effects that size and shape of nanocarriers could have 
on the intracellular uptake of nanomaterials. Several studies were done to address this issue 
using drug/gene release vehicles (polyplexes, liposomes, polystyrene) to find out the size 
effect for the uptake of these nanomaterials in a wide variety of cell lines.[56-59] Some of the 
main outcomes reported on these works are: the size limits for internalization of 
nanoparticles through endocytosis are clearly cell dependent, nanoparticles below 200 nm 
will follow mainly endocytic pathways, particles above this size can be either engulf through 
endocytosis or non-internalized at all, and large particles have to be internalized by 
phagocytic pathways. Recently, with the continued development of inorganic nanoparticles 
as nanocarriers, a high interest has risen about the thorough understanding of the effect of 
structural properties of inorganic nanomaterials (size/shape) toward their endocytic 
16 
 
uptake.[60-63] Outstanding results have been reported in relation to this subject; for instance, 
W. Chan and coworkers found that in the case of spherical-shaped gold nanoparticles 
(AuNPs) the maximum uptake of nanospheres occurred at the diameter size of 50 nm, which 
is in agreement with previous reports. They also found that the internalization of nanorods 
AuNPs is less efficient than nanospheres.[60, 61] They account for these results based on the so 
called “wrapping time” parameter, which describes how a membrane encloses a particle 
based on its surface area.[64] The internalization of nanospheres was more efficient because it 
takes shorter time to wrap a sphere than an entire rod due to the increase in the surface area. 
Our group has also studied the effect of these structural properties (shape and size) on 
the uptake of MSNs by mammalian cells. In this work two nanoparticles were investigated, 
nanorods (600 nm in length and 100 nm in width) and nanospheres (80-100 nm in 
diameter).[65] The cellular uptake and kinetics were evaluated in CHO and human fibroblast 
cells. We found that the uptake of MSNs was both shape and cell-line dependent. CHO cells 
showed a more efficient uptake capacity than fibroblast cells for both materials. Moreover 
the rate of uptake was different in the case of fibroblast cells, for instance spherical-shaped 
MSNs reached 100% uptake in 180 min, while rod-shaped MSNs needed 360 min to achieve 
the same uptake percentage, which is in complete agreement with the “wrapping time” theory 
mentioned above. Other groups have studied similar properties in different variety of cells; 
for example, Vallhov and coworkers studied the effect of MSNs’ size on human monocyte-
derived dendritic cells (MDDC). Two materials with spherical shape, and different size (270 
nm and 2.5 µm) were tested. The authors demonstrated that the size and concentration have 
an effect on the viability, uptake, and immune regulatory markers.[66] They found that smaller 
MSNs in lower concentrations influence the MDDC viability to a minor degree. 
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Interestingly, their results showed that both materials are found in different locations inside 
the MDDC. Recently, C.-Y. Mou, and coworkers also reported on the size effect of spherical 
MSNs toward its internalization on HeLa cells. The authors synthesized MSNs with similar 
surface chemistry, charge, and different sizes (30, 50, 110, 170, and 280 nm). In agreement 
with previous reports, the authors found that a diameter of 50 nm is the optimal size for the 
most efficient endocytosis of MSNs.[67] 
4. Intracellular trafficking 
Once the MSN vehicle has overcome the cell membrane barrier, it has to reach the 
cytoplasm to release its cargo. The understanding of these intracellular pathways that MSNs 
undergoes after its endocytosis could help to improve the design of more efficient drug 
delivery systems. The internalization of the MSNs through endocytosis results in the 
formation of vesicles that capture MSNs present in the extracellular environment. These 
vesicles then undergo a complex series of fusion events directing the internalized MSNs to 
the cytosolic compartment. According to our current knowledge, the series of events after the 
MSNs have been endocytosed can be divided as follow; the material is transported to primary 
endosomes and then to sorting endosomes. From sorting endosomes, a fraction of MSNs is 
sorted back to the cell exterior through recycling endosomes, while the remaining fraction is 
transported to secondary endosomes, which fuse with lysosomes. The MSNs then escape the 
endo-lyso-somes and enter the cytosolic compartment. Once the MSN is in the cytoplasm, 
the material would release its drug/gene cargoes. And finally, the cell would eliminate MSN 
from the cytoplasm through an exocytosis process (Figure 5).[50] Our group has investigated 
the intracellular trafficking pathways of FITC-MSNs, mainly its endosome escape and the 
effect that surface functionalization could have toward this property. We followed the 
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internalization of these materials by confocal microscopy using an endosome marker. We 
found that more negatively charged MSNs materials are able to escape from endosomes, 
while positively charged remained trapped within endosomes at the conditions used in our 
experiment. These results were explained based on the surface charge reversal of MSNs that 
results from transfer of protons ions from bulk solution to its surface under acidic conditions, 
better known as “proton sponge effect”.[31] Y.-C. Chen and coworkers also reported on the 
MSNs trafficking inside the cells. They were able to investigate the endo-lysosomal escape 
of MSNs using LysoTrack-label. Moreover, they found that some of the material was 
localized in the mitochondria, according to the nonyl acridine orange probe.[32] 
5. Cell targeting 
The combination of drug delivery and site targeting to specific cell/tissue populations 
is a key issue in biomedical science; especially in cancer therapy, where the antitumor drugs 
that lack the target specificity result in adverse side effects and have limited effectiveness due 
to unspecific action on healthy cells.[1] Therefore, research efforts are being placed on 
generating cell-targeting drug delivery systems to specifically release the desired drugs to 
unhealthy cells without side damages. Different strategies could be used for cell targeting 
such as chemically attached antibodies, proteins, peptides or specific ligands to MSNs 
carrier. These systems rely on the ability of the targeting agents to selectively bind receptors 
on the cell surface to trigger receptor-mediated endocytosis pathway. Our group reported for 
the first time on the synthesis of a receptor functionalized MSN vehicle. We were able to 
decorate the surface of MSNs with folate groups, which are specific for human cancer cells 
that contain high abundance of α-folate receptors. We further demonstrated that the 
endocytosis of this material is via a receptor-mediated endocytosis and that this process is 
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inhibited by folic acid.[31] Other groups have demonstrated that this strategy is indeed 
successful for the selective targeting and drug release in cancer cells. For instance, M. Lindén 
and coworkers reported on the performance of a MSN-based core-shell-shell system 
containing PEI at the surface of MSN; moreover, the authors attached to the amine groups of 
PEI, folic acid and FITC molecules (FA-PEI-MSN).[68] The particularities of this material 
allowed the authors to study the selective internalization of FA-PEI-MSN on HeLa cells. The 
authors proved that the uptake of this material was an order of magnitude higher in HeLa 
cells versus embryonic kidney epithelial 293 cells (low folate receptors expression). In 
addition, Tamanoi and coworkers successfully demonstrated the target-specific drug release 
of an anticancer drug camptothecin/paclitaxel on cancer cells (PANC-1) using this folate 
functionalization strategy.[69] As we mentioned above other targeting strategies could be 
used. For instance, C.-Y. Mou reported on functionalization of MSNs with monoclonal 
antibody (anti-HER2/neu mAb) for selective targeting of breast cancer cells.[70] Other groups 
have also shown the successful application of mannosylated MSNs nanocarriers as target-
specific systems for gene delivery and photodynamic therapy.[71, 72] Despite all these 
promising examples in vitro, the application of target-specific MSN vehicles in vivo has not 
yet been reported. 
6. Biocompatibility 
To completely take advantage of the potential of MSNs in nanomedicine, full 
attention is required to safety and toxicological issues. Information regarding to 
biocompatibility in vitro, and absorption, biodistribution, retention, degradation, clearance 
and safety of MSNs in vivo is of vital importance for this matter.  The biocompatibility of 
MSNs in vitro with different cells lines has been proved by us and other groups. But 
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surprisingly, despite the great potential that MSNs show for biomedical applications, our 
knowledge of the toxicological effects in vivo exposure is still very limited. This maybe 
because many features can be included as potentially toxic triggers such as surface area and 
size distribution, chemical composition, surface structure, solubility, shape and aggregation.     
The biocompatibility of MSNs in vitro is concentration-dependent and has been thoroughly 
studied in different cell lines. For instance, our group reported on the cytotoxicity of MSNs 
toward HeLa and CHO cells finding that at concentration below 100 µg/mL the material is 
biocompatible.[17, 31] The increase of MSNs concentration to above 200 µg/mL resulted in 
cell damage. The exact mechanism responsible for the cytotoxicity of this type of amorphous 
silica materials is not well understood. Some authors have reported that this material at high 
doses induces cell membrane damage;[73] however, others involve the enhanced of reactive 
oxygen species (ROS) formation by the material to induce toxic oxidative stress.[74] In 
addition, Asefa and co-workers have reported on the inhibition of cellular respiration by 
MSNs.[75] 
As we mentioned above, the structural properties of MSNs can affect their 
biocompatibility, this was cleverly demonstrated by our group in a recent report. In this study 
we reported on the hemolytic properties of MSNs toward mammalian red blood cells 
(RBCs).[76] The cytotoxicity of amorphous silica toward RBCs has been previously reported, 
the mechanism proposed to account for this cytotoxicity is based on the interaction between 
the surface silanol groups and the tetra-alkyl ammonium groups that are found on the 
membrane of RBCs. We synthesized a regular MSN material and compared its properties 
with commercially available amorphous silica material. The solid state NMR experiment 
showed that MSNs contain twice the ratio of (Q2 + Q3)/Q4 sites unreacted than amorphous 
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silica, as a clear indication that the amount of silanols in MSNs is much higher than in 
amorphous silica. Surprisingly, the -potential of MSNs (-35 mV) is lower than the one 
found for amorphous silica (-49 mV), which suggests that most of the silanol groups in 
MSNs are contained inside the nanochannels. When we tested the hemolytic properties of 
these two materials at different concentrations (20 – 100 µg/mL) we found that MSNs are 
non-toxic toward RBCs; on the contrary, amorphous silica induced a high degree of 
hemolysis confirming previous reports. To account for this performance we hypothesized 
that the strong electrostatic interaction between the continuous surface of silanol groups in 
the amorphous silica material with the RBCs membrane is the reason for its hemolytic 
properties. On the contrary, MSNs contain most of the silanol groups inside the 
nanochannels; moreover, their external surface is discontinuous because of mesoporosity, 
which results in a low hemolytic behavior. To further confirm that the silanol groups are 
responsible for the hemolytic properties of amorphous silica and MSNs, both were grafted 
with positive and negatively charged groups. After evaluating the hemolytic properties of 
these modified materials, none of them showed considerable cytotoxicity toward RBCs as a 
confirmation that indeed the silanol groups on the external surface of amorphous silica are 
the reason of its hemolytic properties. This report illustrated that contrary to the cytotoxicity 
of amorphous silica toward RBCs, MSNs showed a high biocompatibility upon the 
concentrations evaluated in this study. This finding offers promising potential for the 
application of MSNs in the fields of biomedicine and biotechnology. This study was recently 
confirmed by Haynes and co-workers using a mesoporous silica coated iron oxide 
nanoparticle.[77] 
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Applications of MSNs in vivo have been recently reported that might give us a 
general idea of their toxicological performance in animals. For instance, D.-M. Huang,[78, 79] 
T. Hyeon,[80] W. Lin,[81] and co-workers have demonstrated the use of MSNs as bio-imaging 
vehicles in vivo. Under the conditions used for their experiments, none of the authors 
observed toxicity effects in vivo during short-term. In addition, T. Hyeon and co-workers, 
followed the biodistribution of the material after 24h of intravenous injection, they found that 
MSNs nanoparticles accumulated mainly in liver, kidney, and spleen.   
Recently, Langer and his group published a systematic investigation on the 
biocomaptibility of MSNs in vitro and in vivo.[82] As we mentioned before, the in vitro 
studies have previously shown that the biocompatibility of MSNs is concentration- and cell 
type-dependent, and this finding was just corroborated in this report. In the case of in vivo 
experiments the authors selected three different routes of administration; subcutaneous, 
intraperitoneal, and intravenous. The subcutaneous administration did not show a significant 
toxicity after long-term investigation on rats (3 months), even though high doses of MSNs 
were introduced (30 mg/mL). In the case of peritoneal administration, the authors found that 
the material is letal to SV129 mice during the first 24h after injection, but reducing the dose 
of material to 1mg/mL or less resulted in complete reduction of the toxicity. The same lethal 
effect as in the peritoneal injection was observed on the intravenous administration. The 
authors hypothesized that this toxicity maybe due to pulmonary embolism and/or thrombosis, 
but the death mechanism is still under investigation.  It is important to mention that due to the 
chemical versatility of MSNs toward further functionalization, the toxicity at high 
concentrations of this material in vivo could be mitigated using polymers, liposomes, 
proteins, and/or other functional groups.[82-84] 
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Another important concern for the application of MSNs as drug delivery nanocarrier 
is what the final fate of the vehicle will be after it has accomplished its diagnostic/therapeutic 
purpose. The ideal situation would be that the material is biologically degraded in harmless 
byproducts, and finally cleared from the animal body through a safe route. Recently two 
studies related to this issue have been published. The authors reported on the degradability 
and clearance of silicon and silica materials in vivo.[84, 85] Because of their chemical similarity 
with MSNs we think that the findings reported in these papers could give us a close insight 
toward the final fate of MSNs in vivo. For instance, M. Sailor and co-workers studied the 
biodistribution of porous silicon nanoparticles. The authors found that the accumulation of 
material is mainly in the mononuclear phagocytic system organs, such as kidney, liver, and 
spleen.[85] A noticeable silicon clearance was observed from the mice body within a period of 
1 week and the material was completely cleared in 4 weeks. The porous silicon nanoparticles 
did not show any considerable toxicity to the mice organs and their growth was similar as the 
control. The mechanism of clearance for these silicon nanoparticles after being degraded, 
presumably by lysosomes and released by cells, is attributed to its decomposition in soluble 
silicic acid followed by excretion through the renal system. 
In a similar research, K. Wang and co-workers reported on the biodistribution an 
elimination of silica nanoparticles.[84] The authors found that these nanoparticles are 
accumulated mainly in the liver, kidney, and urinary bladder after few hours of being 
administrated through an intravenous injection. They also reported that the blood circulation 
time can be modified by coating the nanoparticles with different functional groups. Finally, 
the authors demonstrated that the silica nanoparticles are safely excreted through a renal 
route. 
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We anticipate that the data reported so far about the toxicological properties of MSNs 
in vitro and in vivo could be further improved, because the chemical versatility of MSNs to 
afford materials with better blood circulation times, adsorption-specificity, biodegradability, 
and clearance from animal/human body. We envision that these further MSNs modifications 
will show promising data for its future application as “theragnostic” nanovehicle in clinical 
trials.  
7. Drug delivery systems 
At the beginning of this century, the application of mesoporous silica as drug delivery 
vehicle was proposed.[17, 86] Our group has been the pioneer in the use of MSNs as platform 
for intracellular drug delivery. We have developed DDS based on MSNs capped with solid 
nanoparticles such as cadmium sulfide (CdS-),[17] gold (Au-),[87, 88] and iron oxide (IO-
NPs),[89] and soft nanoparticles such as dendrimers,[53] proteins,[90] and polymers.[46] This 
gatekeeper strategy has allowed us to have site- and time-control of the release of the 
biogenic agent based on stimuli responsive linkers (Figure 6). We have used different 
biocompatible stimuli responsive triggers such as chemical reactions and light. Moreover, we 
have demonstrated that the use of nanoparticles as caps results in “zero premature release” of 
cargo before reaching the targeted site. All these advantages have resulted in promising 
applications of MSNs as drug delivery vehicles in vitro as we will describe below. We 
envision that soon these strategies will be applied to in vivo systems.  
Our first approach to demonstrate the application of MSNs as DDS was based on the 
release of neurotransmitters using CdS-NPs as caps.[17] The CdS-NPs-MSNs system was 
synthesized using MSNs as the guest reservoir and a chemically labile disulfide bond linker. 
This linker was chemically attached to the CdS-NPs to afford the stimuli-responsive 
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gatekeeper approach. MSNs were loaded with biogenic cargoes (adenosine triphosphate 
(ATP), and vancomycin) and their release was triggered by reducing agents (dithiothreitol 
(DTT), and mercaptoethanol (ME). We successfully demonstrated the stimuli-responsive 
release of vancomycin/ATP in solution using DTT and ME as reducing agents. We later 
applied this system in astrocyte cell culture, where the stimuli-triggered release of ATP was 
monitored in an indirect way by the change in concentration of intracellular Ca2+. Although, 
the release of ATP/vancomycin in this study was not intracellular; it demonstrated the utility 
of this material to carry a biogenic molecule without any premature release. In addition, the 
release was carried out in a stimuli-responsive fashion, and the vehicle showed a suitable 
biocompatibility in vitro. Following this first report, we also published on the use of MSNs 
as both gene and drug delivery system. This nanocarrier was synthesized based on MSNs and 
PAMAM dendrimers as caps.[53] Taking advantage of the positive charge of the PAMAM 
dendrimers we demonstrated the intracellular release of the plasmid DNA that encodes for an 
enhanced green fluorescence protein (EGFP) (Figure 7). We also tested the performance of 
the PAMAM-MSNs vehicle against enzymatic cleavage. We found that the PAMAM-MSNs 
material could protect DNA from enzymatic degradation. Interestingly, the gen transfection 
efficacy was better than current commercially available transfection agents. This 
demonstrated the ability of MSNs to carry, protect, transfer and release DNA vectors inside 
the cells. To prove the multi-task properties of this system, Texas red was loaded and 
localized intracellularly by confocal microscopy. In this report we demonstrated for the first 
time that MSNs can be applied as both drug and gene delivery vehicle. 
One of the desirable features for any DDS is to have the ability to move the vehicle at 
will toward a specific-site. Following this idea we developed a MSN vehicle capped with 
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magnetic nanoparticles. In this material we kept the extraordinary advantages of MSNs as 
DDS, such as stimuli-responsive capability via a labile disulfide bond that is triggered using 
the intracellular reducing environment; “zero premature release”;  biocompatibility; and 
efficient uptake by cells.[89] In addition to the above mentioned features we also added the 
ability of moving the nanocarriers to any desired site by means of an external magnetic field 
as we demonstrated in solution and in vitro in this study. This is the first report published on 
the synthesis and application of a drug delivery vehicle based on MSNs capped with 
magnetic nanoparticles. 
As was mentioned above, different stimuli-responsive DDS can be developed based 
on MSNs. The stimuli to trigger these systems can be divided in two main categories; 
internal and external. The internal stimuli, such as change in pH, reducing environment, and 
enzymatic activity, depend upon the homeostasis of the cell. The external stimuli, such as 
light, ultrasound, and electromagnetic field these stimuli can be controlled and thus have the 
advantage of being time- and location-specific.[19] We recently reported on the synthesis and 
application in vitro of MSNs capped with photo responsive AuNPs (PR-AuNPs).[88] The 
working principle of this system is based on the electrostatic interaction between MSNs and 
PR-AuNPs (Figure 8). Upon irradiation with UV light, the umpolung of surface charge leads 
to repulsion of AuNPs releasing the cargo. We demonstrated this concept through photo-
induced release of encapsulated fluorescein dyes. After that, we inoculated human cells (liver 
and fibroblast) with paclitaxel-loaded PR-AuNPs-MSNs and measured the viability of the 
cells. The cell proliferation was inhibited with the drug-loaded PR-AuNPs-MSN material 
after irradiation under mild conditions. We demonstrated for the first time that MSNs capped 
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with AuNPs can be efficiently loaded with drugs and can release inside human cells their 
cargo in a controlled fashion using an external trigger under biological conditions. 
The ability to selectively functionalize the external surface of MSNs opens a wide 
range of possibilities in the field of drug delivery. We can foresee the development of a co-
delivery system where different guest molecules could be loaded to and released in a 
controlled sequence. Indeed, we recently published a study that accomplished this target. We 
developed a glucose-responsive MSN vehicle that contains both insulin and cyclic adenosine 
monophosphate (cAMP). We were able to precisely control the sequence of release of both 
biogenic cargos.[90] The working principle of this system is based on the interaction of 
phenylboronic acid-modified MSNs (BA-MSNs) and gluconic acid-modified insulin (G-Ins) 
that works as cap. This interaction can be disrupted by the addition of different saccharides 
(glucose, fructose, galactose, mannose) that could displace G-Ins from MSNs opening the 
pore. Inside the nanochannels we loaded cAMP, which could be released in a controlled 
fashion after the displacement of G-Ins by saccharides. We successfully proved the release of 
both G-Ins and cAMP using different saccharides and pH conditions. Interestingly, the 
system showed to be selective toward glucose in typical diabetic levels. The system is 
biocompatible at the concentrations needed to have a therapeutic effect. We investigated the 
intracellular release of cAMP with rat pancreatic islet tumor (RIN-5F) cells using a Millipore 
cAMP HTS immunoassay to quantify the amount of cAMP. After comparing with cAMP in 
solution, we demonstrated that cAMP loaded G-Ins-MSNs efficiently released cAMP inside 
RIN-5F. This was further proved by confocal microscopy.     
On the other hand, the versatility of MSNs can be demonstrated by just covalently 
linked a biogenic molecule onto its surface and intracellularly releasing it. This strategy 
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could increase the amount of cargo loaded keeping the “zero premature release” property. 
We demonstrated this concept by developing a cysteine-loaded MSN system. Cysteine is an 
amino acid required for the biological synthesis of glutathione (GSH), which is of vital 
importance for controlling the homeostasis of live cells.[91] We chemically anchored cysteine 
molecules on the surface of MSNs through a labile disulfide linker and measured their 
release. The release was triggered by different reducing agents in solution. The cysteine 
molecules have been chemically incorporated in MSNs with high efficiency through this 
approach. Moreover, we demonstrated the efficient endocytosis and cargo release of this 
material in HeLa cells by flow cytometry and confocal microscopy. We successfully 
demonstrated by a viability assay that this system is roughly 400 times more effective than 
conventional cysteine pro-drug (i.e. N-acetyl cysteine).  
Uncapped MSNs have also shown their efficacy in the release of different cargos. For 
instance, we reported on the successful release of a membrane impermeable protein 
(cytochrome c).[40] To achieve this goal, we synthesized a large pore MSNs (5.4 nm). We 
demonstrated that the enzymatic activity of the cytochrome c after being loaded and released 
in solution was preserved. Besides, we corroborated by confocal microscopy that MSNs can 
efficiently transfer cytochrome c through the cell membrane and release it in the cytoplasm. 
Other biogenic molecules have been released using uncapped MSNs, such as 
camptothecin,[92] propidium iodide,[93] paclitaxel,[55] doxorubicin,[94] and different 
fluorophores.[95] To improve the release of these drug delivery vehicles Zink, Stoddart, and 
co-workers have developed the use of nanoimpellers.[93] The working principle for this 
system is based on the photoisomerization of azobenzene derivatives. The back and forth 
wagging of the azobenzene group acts as a molecular impeller that regulates the release of 
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cargoes from the channels of MSNs. The authors have demonstrated the successful 
application of this strategy in vitro using rhodamine B, propidium iodide, and camptothecin 
as cargoes. 
8. Conclusions 
In this review, we have described the most recent breakthroughs in the application of 
mesoporous silica nanoparticles for intracellular drug delivery. This research has taken us 
through a very exciting journey; starting from the investigation of the endocytic pathways for 
the uptake of MSNs, their intracellular trafficking, the ability of developing site-specific 
systems, their biocompatibility in vivo and in vitro, and finally their application as 
intracellular drug delivery vehicle. The studies reported in this review established the ability 
of the material to be efficiently internalized by cells and released from endosomes. Some of 
the endocytic and trafficking mechanisms have been described, but still some questions have 
to be answered in the near future. For instance, the final fate of MSNs is still unknown. In the 
case of the MSN-based target-specific nanovehicles encouraging results have been obtained 
in vitro, but these systems have not been applied in vivo and therefore its complete success is 
still questionable.  
The investigation of the toxicological properties of nanomaterials is an area that has 
attracted a lot of attention in the last few years, mainly because this is the principal obstacle 
for applying nanomaterials in vivo. This research area for MSNs is still in its infancy; 
however, recent studies of biocompatibility in vivo have shown promising results. We believe 
that these toxicological issues can be overcome by using versatile functionalization schemes. 
The use of MSNs as stimuli-responsive intracellular controlled drug delivery carrier 
using nanoparticles as gatekeepers has demonstrated a complete success in vitro. We 
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envision that new strategies could be developed based on external triggers such as near 
infrared, magnetic field and ultrasound. In addition, the ability of these nanocarriers to 
release the guest molecules in a site- and time-specific fashion has to be tested in vivo. 
Finally, we envision that base on the knowledge that has been generated in the past 
few years, future breakthroughs addressing the synthesis of new nanocarriers and the clinical 
implementation of this nanotechnology will be developed. 
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Table 1. Structural properties of organo-functionalized mesoporous silica nanoparticles. 
 
Samplea Sb 
(m2/g) 
Vb 
(cm3/g) 
MDb 
(nm)
OASb 
(mmol/g)
Shape PSb 
AP- 721.7 0.45 2.37 1.7 Tubular 1-3 m 
AAP- 664.6 0.48 2.59 0.7 Twisted 
Columns 
1-3 m 
AEP- 805.8 0.57 2.60 1.0 Spherical 0.5-2 m 
UDP- 1022.4 0.78 2.86 0.9 Spherical 0.5-2 m 
ICP- 840.1 0.66 2.58 1.5 Spherical 0.1-0.5 m 
CP- 1012.5 0.68 2.35 1.4 Rod 0.5-1 m 
AL- 1080.5 0.65 1.97 1.7 Rod 0.05-0.5 m 
MCM-41 767.1 0.55 2.55  Spherical 0.3-0.6 m 
 
a MSNs were functionalized with: 3-aminopropyltrimethoxysilane (AP-); N-(2-
aminoethyl)-3-amino-propyltrimethoxysilane (AAP-); 3-[3-(2-
aminoethylamino)ethylamino]-propyltrimethoxysilane (AEP-); ureido-
propyltrimethoxysilane (UDP-); 3-isocyanto-propyltrimethoxysilane (ICP-); 3-cyano-
propytriethoxysilane; allyl-trimethoxysilane (AL-) 
b BET surface area (S); Mesopore volume (V); Mesopore diameter (MD); Amount of 
organic group (OAS); and Particle size (PS) 
 
 
 
 
  
39 
 
Table 2. Structural properties of mesoporous silica nanoparticles synthesized with room-
temperature ionic liquids. 
 
RTILs Sb 
(m2/g) 
Vb 
(cm3/g) 
MDb 
(nm) 
Shape/Mesopore Structure 
C14MIM-MSN 729 0.664 2.71 Spherical/Hexagonal 
C16MIM-MSN 924 0.950 3.03 Ellipsoids/Hexagonal 
C18MIM-MSN 893 0.995 3.27 Rod/Pseudo-moiré 
C14OCMIM-MSN 639 0.695 2.61 Tubular/Wormhole 
 
a MSNs were synthesized with: 1-tetradecyl-3-methylimidazolium bromide (C14MIMBr); 
1-hexadecyl-3-methylimidazolium bromide (C16MIMBr); 1-octadecyl-3-methylimidazolium 
bromide (C18MIMBr); and 1-tetradecyl-oxymethyl-3-3methylimidazolium chloride 
(C14OCMIMCl). 
b BET surface area (S); Mesopore volume (V); Mesopore diameter (MD); Amount of 
organic group (OAS); and Particle size (PS) 
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Table 3. Endocytic pathways for the internalization of mesoporous silica nanoparticles. 
 
MSN material Clathrin Caveolae Macropinocytosis
Non-functionalized Yes No Yes 
Receptor Functionalized Yes No No 
Amine-, guanidinio-functionalized No No No 
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FIGURE CAPTIONS 
Figure 1. Mesoporous silica nanoparticles as platform for drug delivery. (A) Nanoparticles 
attached to MSNs as functional gatekeepers. (B) Hydrophobic/hydrophilic guest molecules 
entrapped in the interior of the nanochannels. (C) Stimuli-responsive linkers chemically 
attached to MSN and nanoparticles. (D) Grafting with a protecting polymer such as PEG, 
which shields the MSN surface from interaction with opsonizing proteins. (E) Bioimaging 
agents such as magnetic nanoparticles, quantum dots, or fluorophores. (F) Targeting ligands 
such as antibodies. (G) Complexation with plasmid DNA. (H) Additional ligands such as the 
attachment of cell-penetrating peptides. (I) Incorporation of a diagnostic label. (J) Stimuli-
responsive polymers. (K) Attachment of functional groups that could modify the metabolism 
of cells. 
Figure 2. Scanning electron microscopy images of amorphous silica (left), and mesoporous 
silica nanoparticles (right). 
Figure 3. Poly(lactic acid)-coated MSNs with fluorescence probe inside the channels. This 
system was synthesized based on our ability to selectively functionalize both surfaces 
(external/internal) of MSNs. 
Figure 4. Pathways of mesoporous silica nanoparticles for entry to cells. Large particles are 
internalized by phagocytosis, whereas fluid uptake occurs by macropinocytosis. In the case 
of MSNs material, most of its internalization is via endocytic pathways. These pathways 
differ with regard to the nature of the surface functionalization and structural properties of 
MSNs.  
Figure 5. Intracellular trafficking of mesoporous silica nanoparticles. (A) MSN is wrapped 
through specific (ligand-receptor) and nonspecific (hydrophobic, Coulombic) binding 
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interactions.(B) Once the MSN is internalized, depending on the endocytic pathway, it can be 
delivered to intermediate compartments (for example, caveosome). (C) Later these 
compartments are transported to early endosomes and then to sorting endosomes. From 
sorting endosomes, a fraction of the MSN is sorted back to the cell exterior through recycling 
endosomes (not showed in the scheme). (D) The remaining fraction is transported to 
secondary endosomes, (E) which fuse then with lysosomes. (F) The MSN then escape the 
endo-lysosomes and enter the cytosolic compartment.  
Figure 6. Mesoporous silica nanoparticles have been engineered with nanoparticles that 
work as gatekeepers. These nanoparticles are attached to MSNs through stimuli-responsive 
linkers. This combination has afforded drug delivery vehicles that release its cargo in a 
space- and time-controlled fashion without any “premature release”. 
Figure 7. Mesoporous silica nanoparticles have been used for both gene and drug delivery. 
In this approach we used PAMAM dendrimers attached by a stimuli-responsive linker to the 
MSN as caps. The positive charge of the dendrimer complex to plasmid DNA and a guest 
molecule could be introduced in the nanochannels of the MSN. The release of plasmid DNA 
was successfully demonstrated by the expression of a green fluorescent protein (EGFP).  
Figure 8. The application of external stimuli for the timing- and space-control release of 
guest molecules has been achieved using mesoporous silica nanoparticles. For example, we 
used a photo-responsive linker, which under biocompatible irradiation conditions can release 
its cargo in vitro. 
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Figure 8 
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CHAPTER 3. PHOTO-INDUCED INTRACELLULAR CONTROLLED RELEASE 
DRUG DELIVERY IN HUMAN CELLS BY GOLD-CAPPED MESOPOROUS 
SILICA NANOSPHERE  
 
A paper published on the Journal of the American Chemical Society 
2009, 131, 3462-3463 
Juan L. Vivero-Escoto, Igor I. Slowing, Chia-Wen Wu, and Victor S.-Y. Lin 
 
Abstract 
A gold nanoparticle (AuNP)-capped mesoporous silica nanosphere (MSN)-based 
intracellular drug delivery system (PR-AuNPs-MSN) for the photo-induced controlled 
release of an anticancer drug inside of human fibroblast and liver cells was synthesized, 
characterized, and evaluated. We found that the mesopores of MSN could be efficiently 
capped by the photo-responsive AuNPs without leaking the toxic drug, paclitaxel, in solution 
and in vitro. This “zero premature release” characteristic is of importance for delivery of 
toxic drugs that could produce side effects on healthy cells such as the ones used in 
chemotherapy. Furthermore, we demonstrated that the cargo-release property of this PR-
AuNPs-MSN system could be easily controlled by an external stimulus using a low-power 
photo-irradiation source under biocompatible and physiological condition. We envision that 
our results would play a significant role in designing new generations of “remote control” 
nano-carrier materials for intracellular delivery of a variety of hydrophobic toxic drugs. 
Introduction 
Recent developments in designing surface functionalized mesoporous silica 
nanoparticles (MSNs) have revealed the promising potential of utilizing these structurally 
ordered materials for drug/gene delivery.[1-4] For many practical drug delivery applications, 
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such as chemotherapy, “zero-premature release” and “stimuli-responsive controlled release” 
of the precious and often toxic pharmaceutical cargo are two important prerequisites that 
would impact the therapeutic efficacy and cytotoxicity of drug delivery. Unfortunately, 
constructing drug delivery carriers with control over the location and timing of drug release 
under physiological conditions remains a challenge.   
Recently, several MSN-based controlled-release systems with the “zero-premature 
release” property have been synthesized by using different kinds of pore-blocking caps, such 
as nanoparticles (NPs),[5-7] organic molecules,[8, 9] and supramolecular assemblies.[10, 11] 
Different stimuli-responsive strategies, such as chemical,[5] pH,[9, 12, 13] electrostatic 
interaction,[14] enzymatic,[15] redox,[16] and photo irradiation,[17-21] have been applied as 
“triggers” for uncapping the pores and releasing the guest molecules from MSNs.  Despite 
these burgeoning developments, many of the MSN-based controlled release systems possess 
only one of the two features, but not both, and are unable to function under physiological 
conditions.  For efficient controlled release of toxic drugs in vitro and/or in vivo, it would be 
advantageous to design a capped MSN material that would respond to a non-invasive and 
externally controllable trigger, such as photo-irradiation, under the physiological condition.  
Herein, we report on the synthesis of a gold nanoparticle-capped MSN material for the 
photo-induced intracellular controlled release of an anticancer drug, paclitaxel, inside of 
human fibroblast and liver cells as depicted in Scheme 1. 
Results and Discussion 
We first functionalized the surface of gold nanoparticle with a photo-responsive 
linker (thioundecyl-tetraethyleneglycolester-o-nitrobenzylethyldimethyl ammonium bromide, 
TUNA) by following a procedure reported by Rotello and co-workers[22] with modifications 
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as detailed in the Supporting Information (SI). The organically derivatized gold nanoparticles 
(PR-AuNPs) are positively charged (-potential= +4.2 ± 1.4 mV) in PBS (pH 7.4) with an 
average particle diameter of 5 nm as determined by the transmission electron microscopy 
(Figure S1 of SI).  
We then synthesized a MSN material according to our previously reported method.[11] 
The honey-comb like, MCM-41 type of mesoporous structure was confirmed by TEM 
(Figure 1a) and powder X-Ray diffractometry (Figure S2 of SI).  As shown in Figure 1a, the 
MSN particle is spherical in shape with an average diameter of 100 nm. The N2 sorption 
analysis of MSN further revealed a type IV BET isotherm with a total surface area of 1083 
m2/g.  Also, a narrow BJH pore size distribution was observed with an average pore diameter 
of 3.0 nm (Figure S3 of SI). 
The capping mechanism of this PR-AuNPs-MSN system is based on the electrostatic 
interaction between the positively charged PR-AuNPs and the negatively charged MSN 
material (-potential= -23.8 ± 1.8 mV) in water.  As illustrated in Scheme 1, upon photo-
irradiation, the photo-labile linker covalently attached to the surface of PR-AuNPs would be 
cleaved, resulting in the formation of a cationic compound (1) as well as the negatively 
charged, thioundecyltetraethyleneglycolcarboxylate (TUEC)-functionalized AuNPs (NC-
AuNPs).[22] The charge repulsion between the NC-AuNPs and MSN would then uncap the 
mesopores and allowed the release of guest molecules.  
TEM microscopy was used to confirm the interaction between MSN and PR-AuNPs.  
Figure 1 shows the TEM micrographs of MSN before and after capping with PR-AuNPs.  In 
the case of the uncapped MSN (Figure 1a), the hexagonally packed mesoporous channels 
could be clearly visualized.  In contrast, the TEM micrograph of PR-AuNPs-capped MSN 
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(Figure 1b) shows dark spots on the outside edges of the mesopores, representing the 
aggregation of PR-AuNPs on the exterior surface of MSN. The presence of AuNPs was also 
confirmed by energy dispersive X-ray (EDX) analysis and powder XRD (Figure S4 of SI).   
To investigate the photo-induced controlled release property of the PR-AuNPs-MSN 
system in aqueous solution, fluorescein was used as a model guest molecule.  The 
fluorescein-loaded PR-AuNPs-MSN sample was prepared and the loading of fluorescein was 
determined to be 1.51 µmol/g of MSN as described in SI.  To examine the capping 
efficiency, the fluorescein-loaded PR-AuNPs-MSN sample was first stirred for 21 h before 
irradiation.  Less than 0.003 µmol/g of fluorescein was leached into the aqueous solution. 
This amount of leaching is similar to that of the control MSN sample without capping 
(Figure 2a). The result indicated that the capping strategy was successful with good 
efficiency.  The photo-induced controlled release of fluorescein was investigated at 365 nm 
under low-power (0.49 mW/cm2) UV irradiation for 10 min. The release reached 100% after 
stirring in water for 35 h as depicted in Figure 2a.  The amount of fluorescein released from 
MSN was 0.11 µmol/g. A control experiment without UV irradiation was also carried out. 
No release of fluorescein was observed even after 80 h (Figure 2a). Furthermore, we 
examined the controlled release property at a wavelength (530 nm) that is known to induce 
local heating of AuNPs.[23]  As detailed in Figure S7 of SI, less than 10% release of 
fluorescein was observed under much higher irradiation intensity (3 mW/cm2) than that of 
the aforementioned condition at 365 nm (0.49 mW/cm2). The result indicated that the release 
of fluorescein from PR-AuNPs-MSN was not due to the photothermal effect of AuNP. 
To validate the feasibility of using the PR-AuNPs-MSN system for intracellular drug 
delivery in live human cells, a hydrophobic anticancer drug (paclitaxel) was chosen as the 
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guest molecule for the controlled release study in human liver and fibroblast cells.  We found 
that the paclitaxel-loaded PR-AuNPs-MSN material was endocytosed rapidly by these two 
cell types as determined by flow cytometry as detailed in SI.  After UV irradiation for 10 
min, significant decreases in the cell viability, 44.2 and 43.5%, were observed for liver and 
fibroblast cells containing paclitaxel-loaded PR-AuNPs-MSN, respectively (Figure 2b, c, and 
3). This result indicated that PR-AuNPs-MSN could indeed transport and release paclitaxel 
inside these live human cells under the control of photo-irradiation.  Interestingly, without 
paclitaxel, the PR-AuNPs-MSN material alone, before and after the UV irradiation, was not 
toxic to cells as indicated in Figure 3.  Also, by encapsulating the paclitaxel inside of MSN 
with the PR-AuNPs cap, the cytotoxicity of paclitaxel to liver and fibroblast cells was 
significantly lowered (Figure 3).  
Conclusions 
In conclusion, we have demonstrated that paclitaxel molecules could be encapsulated 
inside of PR-AuNPs-MSN without the undesired drug leaching inside of live human 
fibroblast and liver cells. This “zero premature release” characteristic is of importance for 
delivery of toxic drugs in chemotherapy. Furthermore, we proved that the cargo-release 
property of our PR-AuNPs-MSN system could be easily controlled by low-power photo-
irradiation under biocompatible and physiological condition. We envision that our results 
would lead to a new generation of carrier materials for intracellular delivery of a variety of 
hydrophobic toxic drugs. 
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Figure captions 
Figure 1. (a) TEM micrograph of MSN, the MCM-41 type mesoporous structure is clearly 
visualized with the light-colored parallel stripes and the hexagonally packed spots. (b) TEM 
micrograph of the PR-AuNPs-capped MSN shows the aggregation (dark spots) of the PR-
AuNPs on the exterior surface of MSN. 
Figure 2. (a) Controlled release profile of fluorescein-loaded PR-AuNPs-MSN after UV 
irradiation (), in dark (X), and the control sample, fluorescein-loaded MSN without the 
AuNPs cap ().  Micrographs of human fibroblast cells containing paclitaxel-loaded PR-
AuNPs-MSN before (b) and after (c) UV irradiation. 
Figure 3. Cell viability study of the paclitaxel-loaded PR-AuNPs-MSN material with Human 
fibroblast (a) and liver (b) cells. All samples were UV-irradiated (365 nm) for 10 min. The 
concentration of material used was 10 µg/mL. Dark-gray and light-gray bars represent 
samples without and with irradiation, respectively. 
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Scheme captions 
Scheme 1.  Schematic illustration of the photo-induced intracellular controlled release of PR-
AuNPs-MSN. Upon UV irradiation, the photo-labile linker on the PR-AuNPs was cleaved, 
changing the surface charge property (-potential) of these gold nanoparticles from positive 
to negative. The charge repulsion between the AuNPs and MSN would then uncap the 
mesopores and allowed the release of guest molecules. 
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Appendix: Supporting information 
Reagents and materials. Tetraethylorthosilicate (TEOS) was purchased from Gelest, Inc. 
Cetyltrimethylammonium bromide, trifluoroacetic acid, triisopropylsilane, 5-(2’-
dimethylaminoethoxy)-2-nitrobenzyl alcohol, bromoethane, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, fluorescein, and paclitaxel were purchased from Sigma-
Aldrich, Inc.  Donor Equine serum was purchased from HyClone, Inc. L-alanyl-L-glutamine, 
gentamicin sulfate, and penicillin-streptomycin solution were purchased from Mediatech, 
Inc. All chemicals were used as received. 
Synthesis of negatively charged Gold Nanoparticles (NC-AuNPs). Following a literature 
procedure (Scheme S1),[1,2] Compound 1 (750 mg) were dissolved in dichloromethane 
(DCM), followed by the addition of trifluoroacetic acid (TFA, 2 mL, 26.9 mmol) and 
triisopropylsilane (1.5 mL, 7.32 mmol). The solution was stirred at room temperature for 12 
h. Then the solvent was removed under vacuum. The as-synthesized compound (1.0 g) and 
150 mg of Au-NPs[3] were dissolved in 25 mL of DCM. The mixture was stirred at room 
temperature for 3 days. After that, the solvent was removed under reduce pressure to afford 
the “protected” NC-AuNPs. The solid product obtained was added to 20 mL of MeOH:THF 
(1:1), followed by the addition of 6 mL of aqueous lithium hydroxide (1.0 M). This 
dispersion was stirred at room temperature for 9h. Finally, the solids obtained were 
centrifugated and washed several times to afford NC-AuNPs. 
Synthesis of ethyl-[2-(3-hydroxymethyl-4-nitro-phenoxy)-ethyl]-dimethyl-ammonium 
bromide (2). The synthetic procedure was modified from a literature-reported method,[1] 5-
(2’-Dimethylamino-ethoxy)-2-nitrobenzyl alcohol (400 mg, 1.665 mmol) was dissolved in 
DCM (40 mL) and bromoethane (5.5 mL, 74 mmol) was added slowly. This solution was 
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stirred at room temperature under dark conditions for 48 h. Then, the solvent and the excess 
of bromoethane were removed under vacuum to afford the desired product. 1H-NMR (400 
MHz, DMSO-d6):  8.17 (d, J = 12.4 Hz, 1H), 7.38 (d, J = 4.0 Hz, 1H), 7.09 (dd, J = 12.4, 
4.0 Hz, 1H),  4.85 (s, 2H),  4.58 (t, J = 6.8 Hz, 2H),   3.78 (t, J = 6.8 Hz, 2H), 3.46 (q, J = 9.6 
Hz, 2H), 3.10 (s, 6H), 1.27 (t, J = 9.6 Hz, 3H). 13C NMR (400 MHz. DMSO-d6): 162.5, 
142.9, 140.5, 128.1, 114.3, 113.6, 62.9, 61.9, 60.8, 60.3, 50.9, 8.7 MS(ESI): m/z[M-Br]+: 
269; [M-Br]++: 268. 
Synthesis of photo-responsive AuNPs (PR-AuNPs). NC-AuNPs (50 mg) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC; 63.3 mg; 0.330 mmol) were added to 15 mL of 
nanopure water and stirred for 10 min. To this solution, 57.6 mg of Compound 2 (0.165 
mmol) were added. The final mixture was stirred for 72 h under dark conditions. Finally, the 
solid product was washed several times with dry methanol, and dried under high vacuum. 
Synthesis of mesoporous silica nanoparticles (MSN). The detailed synthetic procedure for 
the preparation and purification of MSN was described in our previous reports.[4,5] 
Characterization of materials. Surface analysis of MSN was performed by nitrogen 
sorption isotherms in a Micromeritics TriStar surface area and porosity analyzer. The powder 
diffraction patterns of MSN were measured by Scintag XDS-2000 powder diffractometer 
using Cu Kα irradiation. Particle morphology was investigated by using Tecnai G2 F20 
transmission electron microscopy operating at 200 kV. 
-potential measurements. The -potential of MSN, NC-AuNPs, PR-AuNPs, were 
measured in a Malvern Nano HT Zetasizer. Each material was tested five times. Solutions 
(500 µg/mL) of each material in PBS buffer (10 mM, pH 7.4) were prepared. After 
sonication of the suspension for 10 min the -potential was measured.  
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Loading experiments. MSN (20.0 mg) was added to 10 mL of a previously prepared 
fluorescein solution (25 µM; PBS solution: 10 mM, pH 7.4). This suspension was stirred for 
24 h. Then, PR-AuNPs (20.0 mg) were added to the suspension, the mixture was stirred for 
another 24 h. After that, the material was centrifuged, washed several times with PBS buffer 
(at least 10) to get rid of any fluorescein physisorbed, and dried under high vacuum. The 
supernatant and all the washings solutions were collected and the amount of fluorescein 
washed was measured using fluorescent spectroscopy (FluoroMax-2, ex: 488 nm, em: 515 
nm). The loading of fluorescein was calculated with the difference between the original and 
the washed amount of fluorescein.  
Releasing experiments. Fluorescein-loaded PR-AuNPs-MSN material (10.0 mg) was 
redispersed in 3 mL of PBS solution. This dispersion was stirred for 21h at room 
temperature. The amount of fluorescein leaked from the material was measured by 
fluorescent microscopy (FluoroMax-2, ex 488 nm, em: 515 nm). Then, the solution was 
irradiated for 10 min either with a hand-held low power (0.49 mW/cm2, Radiometer DSE-
100H/L) UV lamp (Spectroline® Model ENF-240C, 365 nm) or a HBO mercury short arc 
lamp (3.0 mW/cm2, Radiometer DSE-100H/L) filtered through a 530 nm filter ((Brightline® 
FF01). After that, the solution was stirred for more than 40h and the release of fluorescein 
was monitored by fluorescent spectroscopy at different periods of time. 
Loading of paclitaxel into MSN. A solution of paclitaxel (1.5 mg) in DMSO (1.5 mL) was 
added to MSN (10.0 mg). This mixture was let in contact for 24h. After that, the paclitaxel 
physisorbed MSN was washed at least three times with DMSO and finally dried under high 
vacuum.  
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Capping of paclitaxel-physisorbed MSN with PR-AuNPs. PR-AuNPs (5 mg) and 
paclitaxel-physisorbed MSN (5 mg) were added to 1 mL of PBS solution (10 mM, pH 7.4). 
The dispersion was stirred for 24 h. Then the material was centrifuged and washed at least 
twice with DMSO and PBS solution. The material was dried under high vacuum and kept in 
dark until the in vitro experiments were carried out. 
Cell viability study of paclitaxel-physisorbed PR-AuNPs-MSN in human liver and 
fibroblast cells. Liver or Fibroblast cells were seeded in 24-well plates at the concentration 
of 1x105 cells/mL and were incubated for 24h in D-10 medium (Dubelcco Modified Eagle’s 
Medium plus fetal bovine serum, L-alanyl-L-glutamine, gentamicin sulfate, and penicillin-
streptomycin solution). Then, the D-10 medium was replaced by a dispersion of paclitaxel-
physisorbed PR-AuNPs-MSN in D-10 medium (10 µg/mL). The Liver/Fibroblast cells were 
incubated with this dispersion for 12 h. After that, the plates were photo irradiated for 10 min 
with a hand-held low power (0.49 mW/cm2) UV lamp (365 nm). As a control experiment, a 
plate of Liver and Fibroblast cells containing the paclitaxel-physisorbed PR-AuNPs-MSN 
material was kept in dark during the same time. Both Liver and Fibroblast cells samples were 
incubated for another 36 h. Finally, the cytotoxicity of the samples was evaluated by means 
of Guava test and flow cytometry.  
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Table S1. Structural properties of MSN and PR-AuNPs-MSN. The BET surface area, pore 
size and volume of the AuNPs capped MSN decreased dramatically in comparison with the 
one measured for MSN. 
 
Property MSN PR-AuNPs-MSN 
Surface Area (m2/g) 1082.5 124.6 
Pore Volume  (cm3/g) 1.2286 0.2058 
Pore Size (nm) 3.0 --- 
 
 
 
Table S2. -potential measurements of MSN, NC-AuNPs, and PR-AuNPs. 
Material -potential (mV) 
MSN -23.8 ± 1.8 
NC-AuNPs -33.4 ± 1.3 
PR-AuNPs +4.2 ± 1.4 
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Figure captions 
Figure S1. Transmission electron micrographs (TEM) of AuNPs. The size of the 
nanoparticles is between 4-7 nm (Scale bar: 5 nm). 
Figure S2. Powder X-ray diffraction patterns of MSN () and PR-AuNPs-MSN (). The 
original material exhibited hexagonal type mesoporous structure characteristic of MCM-41. 
The PXRD shows a clear decrease in the intensity of the MCM-41 type peaks after capping 
with PR-AuNPs. 
Figure S3. N2 sorption isotherms of MSN () and PR-AuNPs-MSN (). (a) BET nitrogen 
sorption isotherms, and (b) BJH pore size distribution. The blocking of the MSN pores by 
PR-AuNPs was confirmed by the N2 adsorption/desorption isotherms. A change in the shape 
of the isotherm from type IV to type I after capping and the disappearing of the maximum 
peak in the BJH pore size distribution were observed. 
Figure S4. (a) Scanning electron micrograph (SEM) and energy dispersive X-ray (EDX) 
analysis of PR-AuNPs-MSN. (b) Long-angle XRD. The dark spots in the SEM micrograph 
were confirmed as AuNPs by EDX method and its crystallinity was corroborated by long-
angle XRD. 
Figure S5. FTIR spectra of PR-AuNPs. The FT-IR spectra of PR-AuNPs confirmed the 
success of the coupling reaction between NC-AuNPs and the cationic o-nitrobenzyl alcohol 
(see compound 2 in Scheme S2). We observed, the characteristic peaks for aromatic C-H 
(3056, and 3017 cm-1), aliphatic C-H (2924, and 2853 cm-1), ester (1748 cm-1), and aromatic-
nitro (1501 cm-1 and 1324/1275 cm-1) stretching vibrations. 
Figure S6. Micrographs of liver cells containing placlitaxel-loaded PR-AuNPs-MSN; (a) 
before, and (b) after irradiation. 
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Figure S7.  (a) Controlled release profile of fluorescein-loaded PR-AuNPs-MSN after UV 
irradiation at ~365 nm (), and ~530 nm (). (b) UV changes of PR-AuNPs-MSN upon 
irradiation at ~365 nm (/ = 304 nm) and ~530 nm (/ = 304 nm). Irradiation led to a 
decrease in absorption at 304 nm, as an indication of the breakage of the photo-labile ester 
bond. 
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Figure S2 
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Figure S3 
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Figure S5 
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Figure S6 
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Figure S7 
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Scheme captions 
Scheme S1. Synthesis of negatively-charged AuNPs (NC-AuNPs). (a) Compound 1 was 
deprotected from the protecting group (trityl thioether) using TFA/triisopropylsilane in 
DCM. (b) A Murray place-exchange reaction between AuNPs and the deprotected compound 
1 was carried out to afford the ester-NC-AuNPs. (c) Finally, the ester-NC-AuNPs was 
saponified with aqueous lithium hydroxide in THF/MeOH to afford the NC-AuNPs. 
Scheme S2. Synthesis of photo-responsive AuNPs (PR-AuNPs). NC-AuNPs were reacted 
with compound 2 in presence of EDC to afford PR-AuNPs. 
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Scheme 2  
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CHAPTER 4. CELL-INDUCED INTRACELLULAR CONTROLLED RELEASE OF 
MEMBRANE IMPERMEABLE CYSTEINE FROM MESOPOROUS SILICA 
NANOPARTICLE-BASED DRUG DELIVERY SYSTEM  
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2009, 3219 - 3221 
Renato Mortera, Juan L. Vivero-Escoto, Igor I. Slowing, Edoardo Garrone, Barbara Onida, 
and Victor S.-Y. Lin 
 
Abstract 
A mesoporous silica nanoparticle-based (MSN) intracellular cysteine delivery system 
that could be induced and regulated by cell-produced natural antioxidants was synthesized. A 
large amount of cysteine molecules were covalently attached to the silica surface of MSN 
through cleavable disulfide linkers. These cysteine-containing nanoparticles were efficiently 
endocytosed by human cervical cancer cells HeLa. These materials exhibit 450 times higher 
cell growth inhibition capability than that of the conventional N-acetylcysteine pro-drug. 
Introduction 
Intracellular thiols are of vital importance for controlling the homeostasis of live 
cells.[1] For example, glutathione (GSH) is one of the agents responsible for the reducing 
milieu of various cell types.  Recent studies have highlighted the key role of GSH in several 
physiological processes, such as DNA synthesis, microtubular-related processes, immune 
functions, and protection against oxidative damages induced by free radicals and other 
toxicants.[1, 2] The low intracellular concentration of GSH has been attributed to several 
chronic inflammation disorders, which often leads to cancerous,[3] neurodegenerative,[4] and 
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cardiovascular[5] maladies.  A variety of therapeutic methods in promoting GSH biosynthesis 
have been developed for the treatment of these diseases.[6-8]  
The success of these approaches hinges upon the availability of intracellular cysteine 
(Cys).  However, Cys is toxic and unstable in the extracellular media.[9, 10] To circumvent this 
problem, the current state-of-the-art approach is to chemically alter the structures of Cys, so 
that the stability and membrane permeability could be enhanced.  Among these different 
cysteine-derivatives, N-acetylcysteine (NAC) is one of the most widely administered pro-
drugs due to the rapid absorption upon oral ingestion and the high stability in the 
extracellular media.[9, 11]  Despite these advantages, the intracellular release of cysteine from 
NAC is mediated by a specific enzyme-catalyzed process.[9] In many cases, a large quantity 
(extracellular concentration larger than 20 mM) of NAC is necessary.[9]  Also, recent reports 
have demonstrated that high concentrations (>1 mM) of NAC would cause severe damage on 
cellular DNAs.[12, 13] Therefore, the pursuit of alternative intracellular cysteine delivery 
systems that allow rapid transport of active and controllable amounts of Cys into cytoplasm 
continues to be a vigorous research area. 
Recent developments in designing surface-functionalized mesoporous silica nanoparticles 
(MSNs) have shown promising potential in utilizing these materials for the controlled-release 
of different kinds of biogenic molecules, such as pharmaceutical drugs, DNA’s, proteins, and 
imaging agents.[14-18] To the best of our knowledge, however, there is no prior report on the 
application of these mesoporous silica materials for intracellular controlled release of 
cysteine. The simple impregnation or physisorption of Cys inside of the mesoporous silica 
matrix would suffer from rapid leaching of cysteine in water before the cellular uptake of the 
amino acid-silica composite.  
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Herein, we report on the synthesis and characterization of an MSN-based intracellular 
cysteine delivery system (MSN-S-Cys), where the release could be triggered by cell-
produced antioxidants, including nicotinamide adenine dinucleotide hydride (NADH), 
dihydrolipoic acid (DHLA), and glutathione.[19] As depicted in Figure 1, we investigated the 
efficacy of using this MSN-S-Cys for intracellular controlled release of cysteine inside 
human cervical cancer cells HeLa.  The performance of this MSN-S-Cys system was 
compared with NAC in solution, Cys chemically attached via a thioether bond (MSN-Cys) to 
MSN and Cys physisorbed to MSN (MSN+Cys).  We note that the direct comparison with 
solution Cys was not possible because of its high instability.[10] 
Results and Discussion 
To construct the MSN-S-Cys system, we first prepared a mercaptopropyl-
functionalized mesoporous silica nanoparticle (MSN-SH) material via a co-condensation 
method that we have previously reported.[14, 20] The synthesis of MSN-SH is detailed in the 
Supporting Information (SI).  As depicted in Scheme 1, the mercaptopropyl groups of MSN-
SH were first treated with 2,2’-dipyridyl disulfide to yield a 2-pyridinyldisulfanylpropyl 
functionality. A consequent disulfide exchange reaction with L-cysteine gave rise to the 
desired MSN-S-Cys material (Scheme 1). The loading efficiency of MSN-S-Cys was 
determined to be 0.45 mmol/g of MSN, respectively, by means of HPLC and UV/Vis 
spectroscopy (Table S2 of the SI). 
 The honeycomb-like hexagonal mesoporous structure of these surface functionalized 
MSN materials were confirmed by powder X-ray diffraction (XRD) spectroscopy, N2 
isotherms (Figure S1-S2 and Table S1 of the SI), and transmission electron microscopy 
(TEM image of Figure 1). The results of dynamic light scattering (DLS) analysis of MSN-S-
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Cys and MSN+Cys revealed that both materials formed stable suspension in water with 
average particle diameters of 395 and 390 nm, respectively. The surface charge properties of 
these mesoporous silica nanospheres in aqueous solution were also measured. The values of 
zeta potential (ζ) of MSN-S-Cys (-20.1 mV) and MSN+Cys (-19.2 mV) are summarized in 
Table S2 of the SI. 
To test the efficacy of using MSN as the delivery carrier for cysteine, we evaluated 
the release kinetics of cysteine in PBS from MSN-S-Cys material, where Cys molecules are 
covalently anchored on the mesoporous silica matrix. The amount of Cys release was 
measured by HPLC, as described in the SI. We investigated four disulfide-reducing 
antioxidants, dithiothreitol (DTT),[21] DHLA, NADH, and glutathione, as the chemical 
triggers for the controlled release of cysteine molecules from MSN-S-Cys. As shown in 
Figure 2, no leaching of Cys in PBS solution prior to the addition of reducing agents was 
observed; in contrast, the release of Cys from the physisorbed sample was immediate (Figure 
S3 of the SI). As depicted in Figure 2 (inset), within 30 minutes upon the addition of NADH, 
DTT, DHLA and GHS, approximately 99, 90, 70 and 60% of mesopore-loaded Cys was 
released, respectively. The different rates of release could be attributed to the different 
reducing power between each reducing agent. It is interesting to note that the amount of 
cysteine release was clearly controlled by the quantity of reducing agent added to the solution 
as shown in the plot of percent release of Cys versus the concentrations of DTT and 
glutathione (Figure 3).  
 We and others have demonstrated previously that MSN materials could be efficiently 
endocytosed by a variety of cell types.[17, 22-24] To analyze the intracellular controlled release 
properties, we introduced these Cys-containing nanoparticles to human cervical cancer cells 
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HeLa.  As illustrated in Figure 4, the cell proliferation was evaluated 48 hours after the 
addition of 100 µg/mL of the following MSN samples (MSN+Cys, MSN-Cys and MSN-S-
Cys) and NAC in solution at concentrations of 0.1 mM and 20 mM. Approximately 50% of 
cell growth was inhibited in the case of MSN-S-Cys.  It is interesting to note that NAC at the 
concentration of 0.1 mM was ineffective in causing any cell growth inhibition and a high 
concentration (20 mM) is required to reach the same level of inhibition of MSN-S-Cys. This 
finding is consistent with the results reported in literature, where a minimum concentration of 
15 mM is required for NAC to be therapeutically active.[25] In contrast to the high dosage 
requirement of NAC, our results suggested that MSN-S-Cys is indeed a superior drug 
delivery system in inhibiting cell growth of HeLa.  Apparently, the actual amounts of 
cysteine molecules in the systems of MSN-S-Cys and NAC for inhibiting 50% of the cell 
growth of HeLa are very different.  After comparing the amount of Cys and NAC present 
(0.14/60 µmol) we found that MSN-S-Cys is approximately 444 times more effective in 
delivering the membrane impermeable amino acid, cysteine, than the conventional NAC 
approach.  These results further suggest that the cellular uptake process for HeLa to 
internalize MSN-S-Cys must be quite efficient.  We note that the MSN+Cys material, like the 
thioether-functionalized MSN material (MSN-Cys), did not show any significant effect on 
the cell growth inhibition (Figure 4).  
To further examine the cellular uptake of MSN-S-Cys and the intracellular release of 
Cys, we labeled Cys and MSN with two different fluorescent dyes, fluorescein isothiocyanate 
(FITC; green emission) and tetramethylrhodamine isothiocyanate (TRITC; red emission), 
respectively, via a synthetic approach detailed in the SI. The endocytosis of this TRITC-
MSN-S-Cys-FITC material by HeLa cells was monitored by fluorescence confocal 
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microscopy (Figure 5). The observed yellow spots (Figure 5a) represent the superimposed 
fluorescence of the TRITC-labeled MSN and the mesopore-encapsulated FITC-Cys. The 
observed green spots (Figure 5a and b) indicated that the FTIC-Cys molecules were indeed 
released from MSN-S-Cys. This result was further corroborated by externally introducing the 
cell membrane permeable glutathione monoester to enhance the intracellular release of Cys 
in HeLa cells (Figure S6 and 7 of the SI).[26] 
Conclusions 
In conclusion, we have demonstrated that mesoporous silica nanoparticles (MSN) can 
serve as an efficient carrier for the intracellular delivery of cysteine (400 times better than 
NAC). We found that the controlled release of cysteine from MSN-S-Cys could be induced 
and regulated by both artificial and cell-produced natural antioxidants. Also, our results 
indicated that the MSN-S-Cys particles could indeed penetrate the cell membrane of HeLa 
and effectively deliver cysteine intracellularly to inhibit the cell growth of these cancer cells. 
We envision that this MSN-based intracellular cysteine delivery system could serve as a new 
therapeutic method for many cysteine-related diseases and personal health care issues, such 
as HIV infection,[11] cancer,[11] aging,[27] and acetaminophen poisoning.[28] Further 
developments on the utilization of this design principle for constructing novel controlled 
release delivery systems could also bring impacts to other biomedical and biotechnological 
applications. 
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Figure captions 
Figure 1. Schematic representation and TEM image (right) of an MSN-based intracellular 
delivery system of cysteine (MSN-S-Cys). The intracellular controlled-release mechanism of 
cysteine is controlled by the reductive cleavage of the disulfide linkage connecting Cys to 
MSN induced by natural cell-produced antioxidants. 
Figure 2. Cysteine release profiles of MSN-S-Cys (30 mg) in 30 mL of PBS induced by 
NADH (), DTT (■) DHLA (), and Glutathione (○). The percentage release of Cys over 
time using 1 mM reducing agents. No noticeable release was observed in the absence of 
reducing agents (▲). 
Figure 3. Percent release of Cys vs. the concentrations of NADH (), DTT (■) DHLA (), 
and Glutathione (○). All data were measured at 30 minutes after the addition of reducing 
agents. 
Figure 4. Cell growth inhibition study: Amounts (%) of viable HeLa cells after exposing to 
100 μg/mL of MSN+Cys, MSN-Cys, MSN-S-Cys, and solutions of NAC (0.1 and 20 mM) 
for 48 hours. The normal cell growth was shown in the entry (Crtl) without any addition of 
NAC, Cys, or MSN. 
Figure 5. Confocal fluorescence micrographs of TRITC-MSN-S-Cys-FITC inside of HeLa 
cells. a) The green fluorescent spots indicating the intracellular locations of FTIC-Cys, 
whereas the yellow areas represent the superimposing fluorescence of TRITC-labeled MSN 
and FITC-Cys. b) Transmission micrograph of TRITC-MSN-S-Cys-FITC. 
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Scheme captions 
Scheme 1. Synthetic scheme of MSN-S-Cys. The detailed reaction condition of a) is 
described in the Supporting Information. Reactions b) and c) were performed in PBS (pH 
7.4) at room temperature for 8 hours. 
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Appendix: Supporting information 
Reagents and Materials: Tetraethylorthosilicate (TEOS) was purchased from Gelest. N-
hexadecyltrimethylammonium bromide (CTAB), 3-mercaptopropyl trimethoxysilane (MP-
TMS), 3-aminopropyl trimethoxysilane (AP-TMS), 2,2'-dipyridyl disulfide (Aldrithiol-2), 
dithiothreitol (DTT), cysteine (Cys), glutathione (GSH), nicotinamide adenine dinucleotide 
hydride (NADH), dihydrolipoic acid (DHLA), fluorescein isothiocyanate (FITC), N-
acetylcysteine (NAC), fluorescein isothiocyanate (FITC), tetramethylrhodamine 
isothiocyanate (TRITC), and trifluoroacetic acid (TFA) were purchased from Aldrich. 
Methanol, hydrochloric acid, tetrahydrofuran and acetonitrile were purchased from Fischer. 
All chemicals were used as received. Nanopure water (18.1 MHz), prepared from a 
Barnstead E-pure water purification system, was employed throughout all the experiments. 
Synthesis of MCM-41-type mesoporous silica nanoparticles with mercaptopropyl 
functionality (MSN-SH): Following the procedure previously reported,[1] 1.0 g of n-
hexadecyltrimethylammonium bromide (CTAB) was dissolved in 480 mL nanopure water 
and 3.5 mL NaOH(aq) (2.0 M). The solution was stirred for 1 h at 353 K, followed by the 
dropwise addition of 5 mL of tetraethylorthosilicate (22.5 mmol, TEOS). Immediately after 
the injection of TEOS, 1 mL of 3-mercaptopropyl trimethoxysilane (5.4 mmol, MPTMS) was 
introduced to the solution mixture. After stirring for 2 h at 353 K, the resulting solid product 
was filtered, dried under high vacuum. The CTAB surfactant was removed by extraction with 
a solution of 0.5 mL HCl (37.4%) and 50 mL of methanol for 6 h at 333 K.  
Characterization of MSN systems: Powder X-ray diffraction patterns were collected with a 
Scintag XRD 2000 X-ray diffractometer using CuKα radiation (2-theta: 1.5°-10°). Nitrogen 
sorption measurements at 77 K were performed using a Micromeritics TriStar sorptometer; 
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BET specific surface areas have been calculated in the relative pressure range 0.05-0.15 and 
pore size has been evaluated following the BJH method.[2] A JEOL 840A Scanning Electron 
Microscopy, a Tecnai G2 F20 transmission electron microscopy operating at 200 kV and a 
Malvern NANO ZS90 Zetasizer were used to determine the mesoporous particle morphology 
and ζ potential. 
Physisorption of cysteine on the mesopore surface of MSN (MSN+Cys): MSN particles 
(100 mg) were dispersed in a PBS solution of Cys (1 mM). The suspension was stirred for 20 
h at RT. The resulting material was washed several times with PBS solution and dried under 
high vacuum. The amount of Cys absorbed by MSN was quantified by HPLC as detailed 
below. 
Preparation of cysteine-functionalized MSN via a disulfide linkage (MSN-S-Cys): MSN-
SH particles (200 mg) were treated with a solution of 2,2'-dipyridyl disulfide (88 mg) in 200 
mL PBS. After stirring for 8 h at RT, the resulting 2-pyridinyldisulfanylpropyl-functionalized 
MSN product was isolated and washed with copious methanol and PBS buffer. The purified 
material was then introduced to a 200 mL PBS solution of Cys (48 mg) to yield the desired 
MSN-S-Cys product.[3, 4] The amount of Cys bonded to the surface of MSN was quantified by 
UV/Vis spectroscopy and HPLC as detailed below. 
Preparation of cysteine-functionalized MSN via thioether bond (MSN-Cys): Following a 
experimental procedure previously reported in the literature[1,3] 1.0 g of CTAB was dissolved 
into 480 ml of nanopure water and 3.5 ml of NaOH(aq) (2.0 M) and stirred for 1h at 353 K. 
Then, 5 ml of TEOS and 1 ml of  allyltrimethoxysilane were then added drop wise. After 
stirring for 2 hours at 353 K, the products were filtered, washed, and dried under vacuum. To 
wash CTAB out from this material, 500 mg of the as-made MSN were dispersed in a solution 
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of 0.5 ml HCl (37.4%) and 50 ml of methanol and stirred for 6h at 333 K. The material was 
washed several times with methanol and dried under high vacuum. Following the well known 
radical reaction between alkenes and thio compounds,[5] 200 mg of this sample were 
subsequently added to Cys (0.4 mmol) and azobisisobutyronitrile (6 mg, AIBN) in 30 ml of  
dry tetrahydrofuran (THF) for 24 hours in nitrogen conditions with vigorous stirring and UV 
light irradiation(350 nm). 
Controlled release of cysteine: The release profiles were measured by soaking 30 mg of 
Cys-containing MSN sample in 30 mL PBS solution (10 mM, pH 7.3) at RT. Every 15 min, 
the sample was centrifuged and aliquots (0.5 mL) were taken to quantify the amount of Cys 
released from MSN by HPLC. Four different disulfide-reducing agents (NADH, DHLA, 
DTT, and GSH) were used as triggers for the release of cysteine in the case of MSN-S-Cys. 
Cys quantification: HPLC method. A Hitachi Organizer high-performance liquid 
chromatographic system controlled with a Hitachi L-7100 pump, a Hitachi L-7200 
autosampler, a Hitachi L-7455 Diode Array Detector and a Hitachi L-7300 Column Oven 
was employed to evaluate the amount of Cys loaded and released by the samples. The mobile 
phase was 99.9% of nanopure water and 0.1% TFA. It was pumped through a Supelco 
Discovery®C18 column with a flow-rate of 0.2 mL/min at RT. The detector was set at 320 
nm and the peak ascribable to Cys in PBS solution appeared between 8.54 and 8.59 minutes. 
In the case of release with reducing agents both the peaks of GSH (19.1-19.5 minutes) and 
DTT (24.9-25.3 minutes) did not overlap with the Cys signal. To determine the Cys loaded 
by the materials the difference in the concentration of Cys in PBS solution before and after 
contact with the samples was calculated. The calibration curves have been determined using 
PBS solutions of Cys in the range of 0.01 mM – 5 mM.  
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UV-Vis method. The MSN-SH sample was treated in PBS firstly with 2,2'-dipyridyl disulfide 
and subsequently with Cys. This reaction afforded 2-thiopyridone as byproduct. The 
concentration of this molecule was used to quantify the surface coverage of chemically 
accessible thiol groups in MSN-SH and the amount of Cys linked to MSN in MSN-S-Cys by 
means of a HP 8453 UV-VIS system (λ = 354 nm). The calibration curve has been calculated 
using PBS solutions of 2-thiopyridone in the 0.01 mM – 0.1 mM concentration range. 
Synthesis of MSN+Cys, MSN-SH, and MSN-S-Cys labeled with FITC: 200 mg of as-
made MSN-SH or MSN sample were treated at first with a solution of 3-aminopropyl 
trimethoxysilane (0.23 mL) in 30 mL of dry toluene at 370 K for 24h. Then this material was 
added to a solution of FITC (7.75 mg) in 200 ml of methanol and stirred at RT for 24h. The 
CTAB was washed out in acid media as is described above. In the case of MSN+Cys and 
MSN-S-Cys, Cys was linked to FITC labeled-MSN via disulfide bond, as reported above. 
Synthesis of TRITC-MSN-S-Cys-FITC: FITC (39.8 mg, 100 µmol) were added to 100 mg 
of MSN-S-Cys in dry DMSO and stirred for 12h. The product was collected by 
centrifugation and washed several times with DMSO, MeOH and water, and finally dried 
under high vacuum.  Then, TRITC (1 mg, 2.25 µmol) was reacted with AP-TMS (10 µL, 56 
µmol) in DMSO (1.0 mL) for 6h at room temperature. To this solution 50 mg of previously 
prepared MSN-S-Cys-FITC material dispersed in 4 mL of DMSO were added and the final 
mixture was allowed to react for 24 h at 353 K. The final product was recovered by 
centrifugation and washed several times with DMSO and water, and dried under high 
vacuum. 
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Synthesis of TRITC-MSN-Cys-FITC: FITC (39.8 mg, 100 µmol) were added to 100 mg of 
MSN-Cys in dry DMSO and stirred for 12h. The product was collected by centrifugation and 
washed several times with DMSO, MeOH and water, and finally dried under high vacuum. 
TRITC (1 mg, 2.25 µmol) was reacted with AP-TMS (10 µL, 56 µmol) in DMSO (1.0 mL) 
for 6h at room temperature. To this solution 50 mg of previously prepared MSN-Cys-FITC 
material dispersed in 4 mL of DMSO were added and the final mixture was allowed to react 
for 24 h at 353 K. The final product was recovered by centrifugation and washed several 
times with DMSO and water, and dried under high vacuum. 
Intracellular toxicity of MSN-S-Cys in HeLa cells: HeLa cells were seeded in six-well 
plates with a density of 1 x 105 cells ml-1 in 3 mL of D-10 medium (Dubelcco Modified 
Eagle’s Medium with horse serum, L-alanyl-L-glutamine, gentamicin sulfate and penicillin-
streptomycin solution), and incubated at 310 K with a 5% CO2 atmosphere for 24 hours. 
Then, the cells were seeded with different concentration of NAC solution (ranging from 0.05 
to 100 mM), MSN-SH, MSN + Cys, and MSN-S-Cys samples (ranging from 25 to 100 µg 
mL-1) in D-10 serum for other 48 hours. After the incubation each well was washed with PBS 
and the cells were trypsinized, centrifuged, and re-suspended in D-10 medium. Viability was 
determined by the Guava ViaCount cytometry assay (Guava Technologies, Inc.). 
Intracellular toxicity of MSN-S-Cys in HeLa cells in presence of GSH monoester:[6,7] 
HeLa cells were seeded in six-well plates with a density of 1 x 105 cells ml-1 in 3 mL of D-10 
medium (Dubelcco Modified Eagle’s Medium with horse serum, L-alanyl-L-glutamine, 
gentamicin sulfate and penicillin-streptomycin solution), and incubated at 310 K with a 5% 
CO2 atmosphere for 24 hours. Then, the cells were seeded with MSN-S-Cys (100 µg mL-1) in 
D-10 serum for other 24 hours. The cells medium was replaced by GSH monoester in D-10 
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serum (10 mM and 20 mM) and incubated for 2 h. After that, the cells were washed with 
PBS and D-10 serum was added and incubated for other 22h. After the incubation each well 
was washed with PBS and the cells were trypsinized, centrifuged, and re-suspended in D-10 
medium. Viability was determined by the Guava ViaCount cytometry assay (Guava 
Technologies, Inc.). 
Measurement of the internalization of MSN-SH, MSN + Cys, and MSN-S-Cys in HeLa 
cells by flow cytometry: HeLa cells were seeded at the density of 1 x 105 cells per well in 
six-well plates in 3 mL D-10 medium.  After incubation for 48 hours, the D-10 medium was 
replaced by 3 mL of FITC labeled material suspensions at different concentrations (1, 10, 25, 
50, and 100 µg mL-1) in the serum-free DMEM medium for 12 h. All the tests were run in 
triplicate. The cells were washed with medium, harvested by trypsinization and, after 
centrifugation, re-suspended in 0.4% trypan blue PBS solution in order to be analyzed by 
flow cytometry with a Becton-Dickinson FACSCanto cytometer with a DB-FACS Diva 
software. To distinguish the true fluorescence generated by the endocytosed FITC-labeled 
material from the natural autofluorescence of cells, a threshold of fluorescence intensity was 
established by performing the flow cytometry analysis on the cells incubated without FITC-
labeled material. The threshold was set at an intensity of fluorescence slightly above the 
highest value observed for control samples (HeLa cells only). The number of cells with 
endocytosed FITC-labeled material was determined by counting those that show fluorescence 
intensity higher than the threshold. 
Confocal fluorescence microscopy measurements: HeLa cells were seeded at the density 
of 5 x 104 cells per well in six-well plates in 3 mL of D-10 medium.  After incubation for 24 
h, the D-10 medium was replaced by 3 mL of either TRITC-MSN-S-Cys-FITC or TRITC-
104 
 
MSN-Cys-FITC material (15 µg mL-1) in fresh D-10 medium for 12 h. Then the cell medium 
was replaced by a solution of GSH monoester in D-10 serum (10 mM) for 2 h. The cells were 
washed with PBS and the cells were incubated in D-10 medium for other 10h. In the case of 
the samples that were not treated with GSH monoester, the cells in presence of material were 
incubated for 24h. Finally, the cell-plates were then washed with PBS and 3 mL of D-10 
medium were added to each well. An aqueous solution of Hoechst 33258 (5 µg/mL) was 
added to the wells and they were let to rest for 30 min at RT. After replacing the Hoechst-
staining solution with D-10 serum, the TRITC-MSN-S-Cys-FITC/ TRITC-MSN-Cys-FITC 
materials inside of HeLa cells were visualized by means of a Leica TCS NT confocal 
fluorescence microscope system with 100x oil immersion objective. 
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Table S1. Specific Surface Area (SSA), mesopore volume (Vp), pore size (DBJH), d100, cell 
parameter (a), ζ potential (ζ) and average particles diameter (D) values for MSN materials. 
 SSABET (m2/g) Vp (cm3/g) DBJH (nm) d100 (nm) a (nm) ζ (mV) D (nm) 
MSN 1093 1.014 3.02 3.98 4.59 -30.5 380 
MSN-SH* 1012 0.578 2.20 3.83 4.43 -28.8 390 
*EC50 of MSN-SH = 4.3 µg/mL 
 
Table S2. Amount of pharmacological agent (Cys), ζ potential (ζ) and average particles 
diameter (D) of different MSN systems: 
 Cys (mmol g-1) ζ (mV) D (nm) EC50 (µg/mL) 
MSN + Cys 0.41 * -19.2 390 4.0 
MSN-S-Cys 0.45 * -20.1 395 3.6 
* Evaluated by means of HPLC.  
* Evaluated by means of UV after aldrithiol-2 reaction. 
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Figure captions 
Figure S1. Characterization of MSN sample. a) XRD pattern, b) nitrogen sorption isotherms 
at 77 K, c) BJH pore size distribution and d) SEM picture. The material exhibited hexagonal 
type of mesoporous structure characteristic of MCM-41 with a pore size of 3.02 nm and 
particle size of 380 nm. 
Figure S2. Characterization of MSN-SH sample. a) XRD pattern, b) nitrogen sorption 
isotherms at 77 K, c) BJH pore size distribution and d) SEM picture. The material exhibited 
hexagonal type of mesoporous structure characteristic of MCM-41 with a pore size of 2.2 nm 
and particle size of 390 nm. 
Figure S3. Percent release of mesopore-adsorbed cysteine from MSN+Cys material in PBS 
solution (10 mM, pH 7.3). The profile showed a fast release kinetics of Cys from MSN+Cys, 
in less than 60 min roughly 95% of Cys was released in PBS solution. 
Figure S4. Proliferation of HeLa cells treated for 48 hours with different concentrations of 
MSN + Cys (dark gray boxes), MSN-SH (black boxes), and MSN-S-Cys (light gray boxes). 
Graph shows the percentage of cells after each treatment, pointing out the role played by the 
Cys released inside the cell membrane from MSN-S-Cys. 
Figure S5. Proliferation of HeLa cells treated for 48 hours with solutions at different 
concentrations of NAC (dark gray boxes) compared to HeLa control (white boxes). Graph 
shows the percentage of cells after each treatment, stressing a noticeable reduction of 
viability above 10 mM solution. 
Figure S6. Confocal fluorescence images of HeLa cells loaded with TRITC-MSN-Cys-FITC 
(a-e), TRITC-MSN-S-Cys-FITC (f-j), and TRITC-MSN-S-Cys-FITC in presence of GSH 
monoester (k-o). (a, f, and k) green fluoresecnece of FITC labeled Cys, (b, g, and l) red 
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fluorescence of the endocytosed TRITC-labeled MSN, (c, h, and m) yellow spots 
corresponding to the overlapped image of green (Cys-FITC) and red (TRITC-MSN) 
micrographs, (d, i, and n) superimposed micrographs of green (Cys-FITC) and red (TRITC-
MSN) images in presence of nuclei-staining dye Hoechst 33258, and (e, j, and o) overlapped 
image of green (Cys-FITC) and red (TRITC-MSN) with transmission image. 
Figure S7. Cell proliferation inhibition of HeLa cells as a function of the concentration of 
glutathione monoester (GSH*). The glutathione monoester dose-dependent perfomance in 
the cell proliferation inhibition confirm its influence in the intracellular release of Cys from 
MSN-S-Cys. 
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Figure S5 
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Figure S6 
TRITC-MSN-Cys-FITC (Control) 
    
 
TRITC-MSN-Cys-FITC 
    
TRITC-MSN-S-Cys-FITC in presence of GSH monoester (10 mM) 
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Figure S7 
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CHAPTER 5. TUNING THE CELLULAR UPTAKE AND CYTOTOXICITY 
PORPERTIES OF OLIGONUCLEOTIDE INTERCALATOR-FUNCTIONALIZED 
MESOPOROUS SILICA NANOPARTICLES WITH HUMAN CERVICAL CANCER 
CELLS (HeLa)  
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Abstract 
A series of organically functionalized, MCM-41 type mesoporous silica nanoparticle 
materials (PAP-LP-MSN and AP-PAP-MSN) with different pore sizes (5.7 nm and 2.5 nm, 
respectively) were synthesized and characterized. We selectively decorated the exterior 
particle surface of PAP-LP-MSN and the interior pore surface of AP-PAP-MSN with an 
oligonucleotide intercalating phenanthridinium functionality. While phenanthridinium itself 
is a cell membrane impermeable molecule, we demonstrated that both these 
phenanthridinium-immobilized PAP-LP-MSN and AP-PAP-MSN materials could indeed be 
internalized by live human cervical cancer cells (HeLa). We discovered that the PAP-LP-
MSN nanoparticles with the phenanthridium groups located on the exterior surface were able 
to bind to cytoplasmic oligonucleotides, such as messenger RNAs, of HeLa cells resulting in 
sever cell growth inhibition. In contrast, the cytotoxicity of AP-PAP-MSN, where the same 
oligonucleotide intercalating molecules were anchored inside the pores, was significantly 
lowered upon the endocytosis by HeLa cells. We envision that this approach of combining 
the selective functionalization of the two different surfaces (exterior particle and interior pore 
surfaces) with morphology control of mesoporous silica nanoparticles would lead to a new 
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generation of nanodevices with tunable biocompatibility and cell membrane trafficking 
properties for many biomedical applications. 
Introduction 
Recent advancements on the synthesis of mesoporous silica nanoparticles (MSNs) 
have attracted much attention for their unique structural features, such as high total surface 
area (> 800 m2/g), tunable pore diameter (2-10 nm), and narrow particle size distribution[1-5]. 
In contrast to other non-porous solid nanoparticles, MSNs offer two different surfaces, i.e., 
the exterior particle and interior pore surfaces. The chemical accessibility to these surfaces of 
MSNs could be tuned by varying the pore diameters and particle sizes of these materials. By 
taking advantage of this characteristic of MSNs, one can manipulate how these materials 
interact with cell membranes, subcellular organelles, and biological macromolecules, such as 
proteins and oligonucleotides, for drug/gene delivery and bio-sensor applications [6-15]. For 
example, we recently reported on the different hemolytic properties of MSN and amorphous 
silica with live red blood cells (RBC) [16]. We demonstrated that, contrary to the known 
cytotoxicity of amorphous silica towards RBC, MSN exhibits a high biocompatibility at 
concentrations adequate for pharmacological applications. We discovered that the hemolytic 
property of silica is related to the amount of silanol groups accessible to the cell membrane. 
The low hemolytic activity of MSN was attributed to the fact that most of the silanol groups 
are “hidden” inside the mesoporous channels that are not accessible to the cell membrane of 
RBC [16].  
In addition to the interaction between cell membrane and the intrinsic silanol 
functionality of MSN, we also examined the efficiency and mechanism for the endocytosis 
and escape of endosomal entrapment of several MSN materials with their exterior particle 
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surface derivatized with various organic molecules [17, 18]. Our results showed that the 
presence of these different organic functional groups on the exterior particle surface of MSN 
indeed had a pronounced effect on the endocytic efficiency and pathways of MSNs with live 
human cancer cells [17, 18]. However, to the best of our knowledge, no prior study reported in 
the literature on how the properties of cell membrane trafficking and intracellular behaviors 
would be altered if the same organic functional groups would be immobilized on the interior 
pore surface of MSN.  
In this study, we report on a strategy that combines the pore and particle morphology 
control with the organic functionalization of MSN to decorate a selective (interior or 
exterior) surface of the mesoporous nanoparticles with an oligonucleotide-intercalating 
functionality, namely phenanthridium (PAP). The endocytosis efficiencies and the 
interactions with intracellular oligonucleotides of these PAP-functionalized MSNs with 
different chemical accessibility were investigated. In general, molecules with the 
phenanthridinium group, such as ethidium bromide (EtBr) and propidium iodide (PI), are 
excluded from healthy viable cells because of their low permeability through the plasmic 
membrane.  However, it has been reported in the literature that these molecules can penetrate 
damaged plasmic and nuclear membranes of animal cells [19, 20].  They are genotoxic and 
mutagenic because of their strong binding affinity to nuclear DNAs and RNAs via 
intercalation, and thereby blocking the gene replication and transcription processes [21-26].  
Ideally, if one could find ways to carry these strong oligonucleotide intercalators through the 
intact plasmic membrane of a healthy live cell, while preventing them from entering the 
nucleus, it would be possible to design a phenanthridinium-based system for the selective 
sequestration of cytoplasmic oligonucleotides, i.e., messenger RNAs.  
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Herein, we describe the synthesis and characterization of two N-[3-(3,8-diamino-6-
phenyl-5-phenanthridinium)propyl]-3-aminopropyl-functionalized, MCM-41 type 
mesoporous silica nanoparticle materials (PAP-LP-MSN and AP-PAP-MSN) that have the 
same average particle size (300 nm) and different pore diameters (5.7 and 2.5 nm, 
respectively). The large particle sizes of both materials prevent them from entering the nuclei 
of live mammalian cells, suggesting that the endocytosed particles would likely to be 
interacting only with cytoplasmic species. In the case of PAP-LP-MSN, the oligonucelotide 
intercalating PAP groups are located on the external surface of MSN. In contrast, AP-PAP-
MSN contains the same intercalator functionality inside of the mesopores, preventing any 
possibility of interaction with oligonucleotides that are too large in size to penetrate the 2.5 
nm pores.  
As depicted in Figure 1, we examined the cell membrane permeability of the two 
phenanthridinium-functionalized MSN materials with live human cervical cancer cells 
(HeLa).  Interestingly, we discovered that PAP-LP-MSN and AP-PAP-MSN were efficiently 
endocytosed by HeLa cells.  In contrast to the free phenanthridinium molecules that can 
penetrate the nuclear membrane, these organically functionalized MSN particles were not 
able to enter the nucleus and remained in the cytoplasm because of the large particle size.  
Furthermore, our results indicated that phenanthridinium-functionalized MSNs (PAP-LP-
MSN) was able to sequester and bind to cytoplasmic oligonucleotides to inhibit the 
expression of a green fluorescent protein introduced by an extraneous plasmid DNA vector 
(pEGFP1-C1).  We envision that the further developments of these organically functionalized 
MSN materials can lead to a new generation of nanodevices for the manipulation of many 
intracellular biochemical processes. 
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Results and Discussion 
To construct the PAP-LP-MSN and AP-PAP-MSN oligonucleotide intercalating 
systems, we first synthesized mesoporous silica nanoparticle materials (LP-MSN and MSN) 
according to the procedure that we have reported previously [6, 12, 27].  LP-MSN and MSN 
materials exhibited a MCM-41 type of hexagonally packed, channel-like mesoporous 
structure with a monodisperse particle size distribution. The average pore diameter for LP-
MSN was expanded to 5.7 nm in comparison to MSN (2.5 nm) without compromising the 
hexagonal honeycomb mesoporous structure and the spherical particle morphology.  
As depicted in Scheme S1 of the Supporting Information (SI), we functionalized the 
as-synthesized, CTAB-containing LP-MSN and MSN materials with an aminopropyl group 
by grafting an organoalkoxysilane, aminopropyltrimethoxysilane (AP-TMS), onto the 
exterior surfaces of these particles in refluxing toluene.  The resulting AP-LP-MSN and AP-
MSN materials were isolated and purified as described in the materials and methods section. 
We then reacted the commercially available 3,8-diamino-6-phenylphenanthridine with ethyl 
chloroformate in dry pyridine to yield the “ethoxycarbonyl-protected” 3,8-
bisethoxycarbonylamino-6-phenyl-phenanthridine (Compound 1) as shown in Scheme S2 of 
the SI.  Compound 1 was subsequently converted to a 3,8-bis-ethoxycarbonylamino-5-(3’-
propylbromine)-6-phenyl-phenanthridium bromide (Pht-Br) by reacting with 1,3-
dibromopropane in refluxing anhydrous THF.  The Pht-Br was reacted with the 
aforementioned AP-LP-MSN materials to covalently anchor the desired phenanthridium 
functionality on the exterior surface of these mesoporous silica nanoparticles.  The resulting 
phenanthridium functionalized PAP-LP-MSN materials were washed extensively with 
methanol and DMSO to remove any physisorbed phenanthridium derivatives.  Finally, the 
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surfactant CTAB was removed via a previously reported acidic extraction method [12]. The 
ethoxycarbonyl protecting group of the phenanthridium functionality of PAP-LP-MSN was 
also removed during this acid extraction process.  
In the case of AP-PAP-MSN material, the surfactant CTAB was removed from AP-
MSN via acid extraction method as depicted in Scheme S3 of the SI. We then reacted in situ 
AP-TMS and Pht-Br in dry toluene, the resulting organo-silane derivative (PAP-TMS) was 
grafted in the internal surface of AP-MSN by refluxing in toluene as described above. Finally 
the material was washed in acidic conditions to remove the protecting group of the 
phenanthridium functionality of AP-PAP-MSN. 
The mesoporous structures of the PAP-LP-MSN and AP-PAP-MSN materials were 
characterized by powder X-ray diffraction (XRD) spectroscopy, transmission electron 
microscopy (TEM), and nitrogen sorption isotherms (BET method for surface area and BJH 
method for pore size distribution).  The powder XRD measurements of both PAP-LP-MSN 
and AP-PAP-MSN materials exhibited diffraction patterns characteristic of the MCM-41 
type hexagonal mesoporous structure with three pronounced (100), (110), and (200) peaks 
(Figure S1 of the SD).  The honeycomb-like mesoporous structure was further confirmed by 
transmission electron microscopy (TEM) as depicted in Figure 2.  The light-colored spots 
representing the openings of the mesopores of PAP-LP-MSN and AP-PAP-MSN were 
packed in a hexagonal symmetry forming the typical MCM-41 type mesoporous structure.  
Moreover, we observed that these materials are monodisperse particles with an average 
particle diameter of 200 and 320 nm for AP-PAP-MSN and PAP-LP-MSN, respectively 
(Table S1 of the SI).  The N2 adsorption/desorption isotherms of the PAP-LP-MSN material 
revealed a type-IV BET isotherm, which is representative of a cylindrical, channel-like 
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mesoporous structure.  The total surface area was found to be 705 m2/g.  Also, the BJH 
analysis of PAP-LP-MSN indicated a narrow pore size distribution with an average pore 
diameter of 57 Å (Figure S2 and Table S1 of the SI).  In the case of AP-PAP-MSN, the 
material also exhibited a high BET surface area of 669 m2/g and a BJH pore diameter of 25 Å 
(Figure S3 and Table S1 of the SI).   
The presence of phenanthridium functional group on the surface of PAP-LP-MSN 
was confirmed by 13C and 29Si CP-MAS NMR spectroscopy (Figure S4 of the SI).  The 
amounts of phenanthridium functionality on the surfaces of the PAP-LP-MSN and AP-PAP-
MSN were determined to be 0.238 and 0.465 mmol/g, respectively by UV/Vis as described 
in the materials and methods section. 
We have demonstrated in our previous reports that the MSN materials can be 
efficiently endocytosed by various cell types, but cannot penetrate the nucleus membrane of 
live cells because of their large particle sizes [6, 17].  By immobilizing the phenanthridium 
functionality on the surface of MSN particles, we anticipated that the PAP-LP-MSN and AP-
PAP-MSN materials would be able to penetrate the plasmic membrane of live cells.  To 
verify this hypothesis, we measured the effective concentrations (EC50) via flow cytometry 
for the endocytosis of PAP-LP-MSN and AP-PAP-MSN by live human cervical cancer cells 
(HeLa) (Figure 3).  The observed EC50 values, 23.7 and 6.6 μg/mL, for PAP-LP-MSN and 
AP-PAP-MSN, respectively, are within the same order of magnitude with that of pure 
inorganic MSN material (12.0 μg/mL).  The results confirmed that these materials could 
indeed be internalized by live HeLa cells.  
To locate these materials intracellularly, we applied fluorescence confocal 
microscopy to examine the red fluorescence emitting from the phenanthridium groups of 
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PAP-LP-MSN nanoparticles that were endocytosed by HeLa cells.  A series of fluorescence 
images of different cross-sections of PAP-LP-MSN-containing HeLa cells were obtained by 
changing the focal depth every 1.2 μm vertically.  As depicted in Figure 4, DAPI-stained 
nuclei was clearly observed by exciting the cells with a UV laser at wavelengths from 340 to 
365 nm (Figure 4b).  Red fluorescence was observed within the cell bodies of these HeLa 
cells upon excitation at 568 nm (Figure 4c), which strongly indicates that PAP-LP-MSN 
materials were indeed endocytosed by HeLa cells.  The overlapped image of both 
micrographs allows us to conclude that even though PAP-LP-MSN materials are inside of the 
cell, they were not able to penetrate the nucleus (Figure 4d).  
As described previously, phenanthridium compounds, such as ethidium bromide 
(EtBr) are genotoxic and mutagenic [21, 22].  The lethal concentration (LC50) value of ethidium 
bromide with different cell types was determined to be ranging from 0.12 to 5.13 mg/L (0.3 
to 13 μM) (30, 31).  In contrast to the free molecular ethidium bromide that cannot 
effectively penetrate intact cellular membrane, the phenanthridium functionality is covalently 
attached to the surface of mesoporous silica nanoparticles in the cases of PAP-LP-MSN and 
AP-PAP-MSN.  As described above, both PAP-LP-MSN and AP-PAP-MSN could be 
efficiently uptaken by HeLa cells.  Presumably, the levels of cytotoxicity of PAP-LP-MSN 
material should be significantly higher than that of EtBr due to the higher membrane 
permeability. To examine the cytotoxicity of PAP-LP-MSN and AP-PAP-MSN, we 
conducted a cell viability (Guava) test of these materials with live HeLa cells.  As illustrated 
in Figure 5, the cell growth inhibition effects of both materials are dosage dependent and the 
corresponding levels of cytotoxicity of PAP-LP-MSN (LC50 = 66 mg/L; 15.75 μM) and AP-
PAP-MSN (LC50 > 100 mg/L; 28.2 μM) are not higher than those of free phenanthridium 
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molecules.  It is interesting to note that, in the case of PAP-LP-MSN, the LC50 value is at 
least twice higher than AP-PAP-MSN material (Figure 5), even the amount of 
phenanthridium group grafted is almost twice smaller in PAP-LP-MSN (0.238 mmol/g) than 
AP-PAP-MSN (0.465 mmol/g).  These results suggested that our phenanthridium-
functionalized PAP-LP-MSN material could perhaps bind to those oligonucleotides that are 
present in the cytoplasm and could not access and intercalate to the nuclear oligonucleotides. 
But in the case of AP-PAP-MSN the cytotoxicity should be lower because even the 
phenantridium group is efficiently internalized into HeLa cells the group is grafted inside the 
pores of the material, which avoid most of the contact with cytoplasmic oligonucleotides. 
To verify the above mentioned hypothesis and to investigate the mechanism of cell 
growth inhibition, we stained the RNA molecules of live HeLa cells (5 × 104 cells in 3 mL 
D-10 medium) with a green fluorescent RNA marker (SYTO RNA®Select™; 500 nM) in the 
presence of PAP-LP-MSN (40 μg/mL).  The endocytosis of PAP-LP-MSN into these RNA-
stained HeLa cells was monitored by fluorescence confocal microscopy (Figure 6).  The 
observed green fluorescent spots of SYTO®RNASelect™ in Figure 6a represent the 
locations of intracellular RNAs, whereas the red fluorescent areas are the positions of PAP-
LP-MSN particles inside the HeLa cells (Figure 6b).  Interestingly, after 22 hours of 
incubation, most of the cytoplasmic RNAs were localized in specific spots inside the cell 
body.  By superimposing the green (SYTO®RNASelect™) and the red (PAP-LP-MSN) 
fluorescence images, we found that both cytoplasmic RNAs and PAP-LP-MSN particles 
coincided at the same spots as illustrated by the orange-colored (red + green) fluorescent 
spots in Figure 6c.  This result strongly suggested that the intracellular RNA molecules were 
sequestered and bound to the PAP-LP-MSN particles. 
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To investigate whether there was the same effect with AP-PAP-MSN, the material 
was introduced to the RNA-stained HeLa cells and the endocytosis of these nanoparticles 
was monitored and analyzed by fluorescence confocal microscopy.  As depicted in Figure 7a-
c, the AP-PAP-MSN particles could indeed be internalized by live HeLa cells.  In contrast to 
the case of PAP-LP-MSN, the cytoplasmic RNAs were not localized in a few spots as 
depicted by the green fluorescent areas in Figure 7a.  On the other hand, the AP-PAP-MSN 
particles appear to be localized inside the cells as represented by the red fluorescent spots 
shown in Figure 7b.  The majority of RNA molecules apparently were not sequestered by the 
AP-PAP-MSN material since there were only a few orange-colored spots that could be 
observed in the overlapped micrograph (Figure 7c).  By comparing this result with those of 
PAP-LP-MSN (Figure 7d-f) and the RNA-stained HeLa cells (Figure 7g-i), it was obvious 
that a high level of RNA-binding could be achieved by anchoring the phenanthridium groups 
on the exterior surface of MSN.  In addition, we have conducted a control experiment, where 
the RNA marker and non-functional MSN or LP-MSN were mixed and introduced to HeLa 
cells, and the same confocal fluorescence studies were performed on these samples.  As 
shown in Figure S5 of the SI, we found no localized green fluorescence spots inside the cells 
indicating that the cytoplasmic oligonucleotides were not sequestered to the locations of 
MSN or LP-MSN nanoparticles.  These results clearly indicated that the binding between the 
RNAs and these MSN nanoparticles depends on the accessibility of the phenanthridium 
functionality to the targeted oligonucleotides and not due to some non-specific surface 
adsorption between oligonucleotide and silica.  
To rule out the possibility that the spots of orange-colored fluorescence were the 
outcome of the surface adsorption of the green fluorescent RNA marker on the red 
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fluorescent PAP-LP-MSN, and not from the intercalation of phenanthridium to the RNA, we 
examined the binding between the PAP-LP-MSN material and yeast tRNA in PBS buffer 
(pH 7.4) by fluorescence emission spectroscopy.  The suspension of these species was 
excited at a wavelength of 450 nm and the intensity of fluorescence emission λmax (520 nm) 
of phenanthridium was measured.  Upon the introduction of green fluorescent RNA marker 
to the suspension of PAP-LP-MSN, we did not observe any increase of the fluorescence 
intensity of the phenanthridium group at 520 nm.  As was previously reported in the literature 
[28-30], the fluorescence intensity of phenanthridium increases upon intercalation to the base-
pairs of oligonucleotides.  As shown in Figure S6 of the SI, the fluorescence intensity at 520 
nm was significantly enhanced when the yeast tRNA was added to the suspension of PAP-
LP-MSN.  This result confirmed that PAP-LP-MSN could indeed bind to the yeast tRNA 
molecules via intercalation. 
To further confirm that the PAP-LP-MSN materials could sequester and bind to 
cytoplasmic oligonucleotides, we introduced an extraneous plasmid DNA (pEGFP-C1) that 
is encoding for an enhanced green fluorescence protein (EGFP) to HeLa cells via a gene 
transfection method that we have developed and reported previously[6].  We cultured and 
transfected two batches of HeLa cells with the pEGFP-C1 DNA for 2 h.  As we previously 
demonstrated, the endocytosis of this gene transfection system into the HeLa cells took place 
within 1 h [6].  In one of the two cultures, we introduced PAP-LP-MSN, while the cells in the 
other culture was used as the control sample without PAP-LP-MSN.  The expression of 
EGFP in both cultures was evaluated using fluorescence microscopy after 32 h of the 
introduction of PAP-LP-MSN.  Figure 8a shows the successful expression of EGFP (green 
spots) in the control sample. In contrast, no expression of EGFP was observed in the culture 
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where the PAP-LP-MSN was added (Figure 8b).  The result clearly indicated that PAP-LP-
MSN material was able to inhibit the gene transfection and the expression of EGFP. 
Conclusions 
We have demonstrated that, by covalently immobilized the oligonucleotide 
intercalator phenantridium group on either the exterior particle or interior pore surface of 
mesoporous silica nanoparticles materials, the cell membrane impermeable PAP functionality 
could be brought into the cytoplasm of live HeLa cells efficiently. We found that the 
endocytosis efficiency of AP-PAP-MSNs is higher than that of PAP-LP-MSNs, which is 
consistent with our previous observation, i.e., the more positively charged MSN particles are 
more cell membrane permeable[17]. While the amounts of PAP on the surface of PAP-LP-
MSN is only 50% of that of AP-PAP-MSNs, our result indicated that the PAP-LP-MSNs 
material could indeed bind to intracellular oligonucleotides leading to significant inhibition 
of protein biosynthesis and cell growth. In contrast, the same intercalator group anchored on 
the interior surface of AP-PAP-MSN did not exhibit any interaction with cytoplasmic 
oligonucleotides. The pronounced difference in the intracellular behavior of these MSN 
materials could be attributed to the size discrimination effect preventing the oligonucleotides 
from accessing the PAP groups inside of AP-PAP-MSN. We envision that this approach of 
combining the selective surface functionalization with morphology control of mesoporous 
silica nanoparticles would lead to new intracellular nanodevices with tunable 
biocompatibility and cell membrane trafficking properties. These materials could play a key 
role in manipulating various intracellular processes for many biomedical and 
biotechnological applications. 
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Figure captions 
Figure 1. Schematic representation of the endocytosis of AP-PAP-MSN/PAP-LP-MSN into 
HeLa cells and binding to cytoplasmic oligonucleotides. 
Figure 2. Transmission electron micrographs (TEM) of AP-PAP-MSN (a, b) and PAP-LP-
MSN (c, d). The typical hexagonal array of MCM-41 type mesoporous structure is visualized 
by the parallel strips and the light-colored spots in the micrographs. 
Figure 3. Cell uptake of PAP-LP-MSN () and AP-PAP-MSN () as a function of their 
concentration.  
Figure 4. Confocal fluorescence images of HeLa cells with PAP-LP-MSN inside the cell 
body. (a) Phase contrast of the cells, (b) DAPI-stained nuclei, (c) red fluorescence of the 
endocytosed PAP-LP-MSN, and (d) the overlapped image of blue (nuclei) and red (PAP-LP-
MSN) spots.  
Figure 5. Cell growth inhibition of HeLa as a function of the concentration of AP-PAP-MSN 
(light-grey bars), and PAP-LP-MSN (dark-grey bars). 
Figure 6. Confocal fluorescence images of HeLa cells with PAP-LP-MSN inside the cell 
body in the presence of RNA-staining dye (SYTO®RNASelect™) after 22 h of incubation. 
(a) SYTO®RNASelect™ stained cells, (b) red fluorescence of the endocytosed PAP-LP-
MSN, and (c) the overlapped image of green (SYTO®RNASelect™) and red (PAP-LP-
MSN) spots.  
Figure 7. Confocal fluorescence images of HeLa cells loaded with AP-PAP-MSN (a-c), 
PAP-LP-MSN (d-f), and control (g-i) in the presence of SYTO®RNASelect™. (a, d, and g) 
SYTO®RNASelect™ stained cells, (b, e, and h) red fluorescence of the endocytosed PAP-
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LP-MSN, and (c, f, and i) the overlapped image of green (SYTO®RNASelect™) and red 
(PAP-LP-MSN) spots.  
Figure 8. Fluorescence images of HeLa cells transfected by the pEGFP-C1 DNA vector-
coated G4-PAMAM-MSN system. (a) Phase contrast image of the cells and (b) Fluorescent 
image of the cells expressed the enhanced green fluorescent proteins (EGFP). (c) Phase 
contrast image and (d) fluorescent image of the cells treated with PAP-LP-MSN. 
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Appendix: Supporting information 
Reagents and materials. Tetraethylorthosilicate (TEOS) was purchased from Gelest. Ethyl 
chloroformate was purchased from Acros. Cetyltrimethylammonium bromide, pyridine 
(anhydrous), 3-aminopropyltrimethoxysilane (AP-TMS), 3,8-diamino-6-phenyl-
phenanthridine, 1,3-dibromopropane, 4,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI), and PAMAM dendrimer (Generation 4) were purchased from Aldrich.  
SYTO®RNASelect™ RNA marker, and yeast tRNA were purchased from Invitrogen, Inc.  
Plasmid DNA encoding EGFP (Living Colors® pAcGFP1-C1 Vector) was purchased from 
Clontech.  Donor Equine serum was purchased from HyClone. L-alanyl-L-glutamine, 
gentamicin sulfate, and penicillin-streptomycin solution were purchased from Mediatech, 
Inc. All chemicals were used as received. 
Synthesis of mesoporous silica nanoparticles (MSN and LP-MSN). The detailed synthetic 
procedures for the preparation and purification of these materials were described in our 
previous reports[1,2,3]. 
Synthesis of 3,8-bis-ethoxycarbonylamino-6-phenyl-phenanthridine. The synthetic 
procedure was modified from a literature-reported method[4].  3,8-Diamino-6-
phenylphenanthridine (2.0 g, 7.01 mmol) was dissolved in dry pyridine (14.4 mL, 178.04 
mmol), followed by the addition of ethyl chloroformate (1.44 mL, 15.08 mmol) at 25 °C.  
The dark red solution was slowly stirred at room temperature for 5 h, and then poured into 
cool water.  The yellow precipitates were isolated to yield the desired 3,8-bis-
ethoxycarbonylamino-6-phenyl-phenanthridine. 1H-NMR (400 MHz, DMSO-d6): δ 10.04 (s, 
1H, NH, 3-Etoc), 10.00 (s, 1H, NH, 8-Etoc), 8.73 (d, J = 9.2 Hz, 1H, H1), 8.63 (d, J = 9.2 Hz, 
1H, H10), 8.32 (s,1H, H7), 8.22 (d, J = 1.2 Hz, 1H, H4), 7.96 (d, J = 7.6 Hz, 1H, H9), 7.81 
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(dd, J = 9.2 Hz, J = 2.0 Hz, 1H, H2), 7.72-7.57 (m, 5H, 6-Ph), 4.19 (q, J = 6.8 Hz, 2H, CH2, 
3-Etoc), 4.11 (q, J = 7.2 Hz, 2H, CH2, 8-Etoc), 1.28 (t, J = 6.8 Hz, 3H, CH3, 3-Etoc), 1.22 (t, 
J = 7.2 Hz, 2H, CH2, 8-Etoc). 13C NMR (400 MHz, DMSO-d6): δ 161.0, 154.3, 154.2, 143.8, 
140.0, 138.6, 130.3, 129.3, 128.9, 125.1, 123.8, 123.4, 119.6, 119.2, 116.9, 115.7, 61.1 (CH2, 
3, and 8-Etoc), 15.2 (CH3, 3-Etoc), 15.1 (CH3, 8-Etoc).  MS (ESI): m/z [M]+, 429.2; [M+1]+, 
430.2 
Synthesis of 3,8-bis-ethoxycarbonylamino-5-(3’propylbromine)-6-phenyl 
phenanthridium bromide (Pht-Br). Following a literature procedure[5], 3,8-bis-
ethoxycarbonylamino-6-phenyl-phenanthridine (400 mg, 0.93 mmol) was dissolved in 20 mL 
of dry THF.  1,3-Dibromopropane (3.6 mL) was added to the solution.  The reaction mixture 
was refluxed for 9 days at 65 °C. The resulting solid product was filtered, washed with 
copious THF and dried under high vacuum to yield the purified Pht-Br.  1H-NMR (400 MHz, 
DMSO-d6): δ 10.37 (s, 1H, NH, 3-Etoc), 10.23 (s, 1H, NH, 8-Etoc), 8.90 (d, J = 9.0 Hz, 1H, 
H1), 8.81 (d, J = 9.0 Hz, 1H, H10), 8.57 (s,1H, H7), 8.38 (s, 1H, H4), 8.15 (d, J = 7.6 Hz, 1H, 
H9), 7.85 (d, J = 9.2 Hz, 1H, H2), 7.80-7.74 (m, 5H, 6-Ph), 4.69 (m, 2H, H1’), 4.19 (q, J = 
6.8 Hz, 2H, CH2, 3-Etoc), 4.10 (q, J = 7.2 Hz, 2H, CH2, 8-Etoc), 3.56 (t, J = 6.2 Hz, 2H, 
H3’), 2.46 (m, 2H, H2’), 1.28 (t, J = 6.8 Hz, 3H, CH3, 3-Etoc), 1.20 (t, J = 7.2 Hz, 2H, CH2, 
8-Etoc). 13C NMR (400 MHz, DMSO-d6): δ 161.7, 154.3, 154.1, 142.8, 142.4, 141.6, 140.1, 
131.9, 131.0, 129.4, 128.2, 127.6, 124.5, 124.3, 121.6, 120.1, 116.7, 115.6, 61.5 (CH2, 3-
Etoc), 61.4 (CH2, 8-Etoc), 47.5 (C1’), 33.2 (C3’), 31.2 (C2’), 15.2 (CH3, 3-Etoc), 15.1 
(CH3, 8-Etoc). MS (TOF MS EI): m/z [M]+, 551.4 
Synthesis of the exterior grafted amino propyl MSN (AP-MSN and AP-LP-MSN). The 
CTAB-containing MSN or LP-MSN (1.0 g) and 1.0 mL (5.73 mmol) of 
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aminopropyltrimethoxysilane (AP-TMS) were added to 100 mL dry toluene.  This reaction 
mixture was refluxed for 24 h.  The resulting aminopropyl-grafted, CTAB-containing AP-
MSN or AP-LP-MSN was washed with copious water and methanol, and dried under high 
vacuum. To remove CTAB, 1.0 g of CTAB-containing AP-MSN or AP-LP-MSN was added 
to a solution of 1.0 mL of HCl (37%) in 100 mL of methanol.  This mixture was refluxed at 
60 °C for 6h. The resulting solid was washed with methanol and water; and finally dried 
under high vacuum to afford AP-MSN or AP-LP-MSN 
Synthesis of “ethoxycarbonyl-protected” phenanthridium aminopropyl LP-MSN (PAP-
LP-MSN). AP-LP-MSN (250 mg) and Pht-Br (75 mg, 0.118 mmol) were added to 50 mL of 
dry toluene.  The mixture was refluxed for 24 h.  The solid product was filtered, washed 
several times with methanol and DMSO.  The material was then dried under high vacuum.  
The amount of Pht-Br grafted to the MSN material was determined by measuring the solution 
concentrations of Pht-Br before and after the reaction. The UV/Vis absorption profiles of 
Pht-Br in methanol and DMSO were carefully calibrated (MeOH: λ = 440 nm, ε = 833.33 M-
1, R2 = 0.993; DMSO: λ = 435 nm, ε = 1000 M-1, R2 = 0.999).  To remove the 
ethoxycarbonyl-protecting group, 200 mg of the as-synthesized PAP-LP-MSN material was 
refluxed for 6 h in a solution of concentrated hydrochloric acid (0.2 mL) in 20 mL of 
methanol, followed by washing with copious deionized water and methanol.  The isolated 
solid was dried under high vacuum. 
Synthesis of the interior grafted phenanthridium aminopropyl MSN (AP-PAP-MSN). 
We first prepared the phenanthridium-aminopropyltrimethoxysilane (PAP-TMS) by reacting 
Pht-Br (63.1 mg, 0.10 mmol) with AP-TMS (20 μL, 0.113 mmol) and triethylamine (14 μL, 
0.10 mmol) in 10 mL of refluxing toluene for 24 h.  This solution was added to 40 mL of dry 
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toluene containing 250 mg of AP-MSN.  The mixture was refluxed for 48 h under nitrogen.  
The resulting AP-PAP-MSN material was isolated through filtration and washed with 
copious methanol and DMSO. Finally, the product was acid washed to deprotect the PAP 
functionality. The purified final product was dried under high vacuum. 
Characterization of materials. Surface analysis of the aforementioned materials was 
performed by nitrogen sorption isotherms in a Micromeritics TriStar surface area and 
porosity analyzer.  The powder X-Ray diffraction patterns of these mesoporous materials 
were measured by a Scintag XDS-2000 powder diffractometer using Cu Kα irradiation.  
Solid-state 13C and 29Si crossed polarization magic angle spinning NMR (CP-MAS NMR) 
measurements of PAP-LP-MSN were obtained from a Bruker MSL-300 spectrometer 
equipped with a Bruker 4 mm rotor MAS probe. Particle morphology was investigated by 
using a Tecnai G2 F20 transmission electron microscopy operating at 200 kV. 
Cytotoxicity measurements. Viability assays of the HeLa cells in the presence and absence 
of PAP-LP-MSN and AP-PAP-MSN were studied by Guava ViaCount assay (Guava 
Technologies, Inc.). HeLa cells were first seeded in six-well plates with a density of 1 × 105 
cells/mL in 3 mL of D-10 medium (Dubelcco Modified Eagle’s Medium plus horse serum, 
L-alanyl-L-glutamine, gentamicin sulfate, and penicillin-streptomycin solution), and set in an 
incubator at 37 °C in a 5% CO2 atmosphere for 24 h.  After that, the media of the wells was 
replaced with freshly prepared D-10 media containing different concentrations of PAP-LP-
MSN and AP-PAP-MSN materials ranging from 0 to 100 μg/mL, and the wells were set back 
into the incubator at 37 °C and 5% CO2 for 2 days.  The plates were then removed from the 
incubator, the media of each well was discarded, each well was washed with phosphate saline 
buffer (PBS) and the cells were trypsinized, centrifuged, and re-suspended in D-10 medium.  
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The cells in the re-suspended media were then counted and their viability was determined by 
the Guava ViaCount cytometry assay. 
Confocal fluorescence microscopy measurements. HeLa cells were seeded at the density 
of 5 × 104 cells per well in six-well plates in 3 mL D-10 medium with coverslips at the 
bottom of the wells.  After incubation for 24 h, the D-10 medium was replaced by 3 mL of 
PAP-LP-MSN or AP-PAP-MSN (50 μg/mL) in the serum-free DMEM medium for 24 h. The 
cell-plated coverslips were then washed with PBS and soaked for 30 min in 3 mL of 4’,6-
diamidino-2-phenyindole dihydrochloride (DAPI; 5.7 μM) and formaldehyde (3.7%) in 100 
mM PBS buffer pH 7.44.  The DAPI-stained coverslips were examined by a Leica TCS NT 
confocal fluorescence microscope system with a 100x oil immersion objective. DAPI-stained 
nuclei fluorescence micrographs were observed by exciting the cells with a UV laser at 
wavelengths from 340 to 365 nm.  The red fluorescent PAP-LP-MSN and AP-PAP-MSN 
materials inside of the HeLa cells were visualized by excitation at 568 nm with a Krypton 
laser. 
Imaging PAP-LP-MSN and AP-PAP-MSN inside HeLa cells in presence of 
SYTO®RNASelect™. HeLa cells were seeded at the density of 5 × 104 cells per well in six-
well plates in 3 mL D-10 medium with coverslips at the bottom of the wells.  After 
incubation for 24 h, the D-10 medium was replaced by 3 mL of PAP-LP-MSN or AP-PAP-
MSN (40 μg/mL) in the D-10 medium for 22 h.  The cell-plated coverslips were then washed 
with PBS twice and fixed by soaking them in 3 mL of methanol pre-chilled at 20 °C for 10 
min.  Methanol was then removed and the coverslips were washed twice with PBS. The cells 
were treated with SYTO®RNASelect™ green fluorescent cell stain (3 mL, 500 nM) in PBS 
and incubated for 20 min at room temperature.  The staining solution was then removed and 
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the cells were rinsed twice with PBS.  Finally, an aqueous solution of DAPI (6 μM) was 
added to the wells containing the coverslips and they were let to rest for 30 min at room 
temperature.  After rinsing with PBS, the DAPI and RNASelect-stained coverslips were 
placed in microscope slides and examined by a Leica TCS NT confocal fluorescence 
microscope system with a 100x oil immersion objective.  The green fluorescent 
SYTO®RNASelect™ marker was excited at 488 nm with an Argon Laser.  The red 
fluorescent PAP-LP-MSN and AP-PAP-MSN materials inside of HeLa cells were visualized 
by excitation at 568 nm with a Krypton laser.  PAP-LP-MSN/AP-PAP-MSN is considered to 
be bound to the intracellular RNAs when the green and the red spots are co-localized to give 
an orange color. 
Binding study of PAP-LP-MSN and yeast tRNA. PAP-LP-MSN (2.0 mg) was introduced 
to 1.0 mL of PBS solution (pH= 7.4, 10 mM), followed by the addition of 5 μL yeast tRNA 
(10 mg/mL).  The fluorescence emission of the mixture was measured by FluoroMax-2 
fluorimeter (λex= 450 nm). 
Binding study of PAP-LP-MSN and RNA marker dye. PAP-LP-MSN (2.0 mg) was 
introduced to 1.0 mL of PBS solution (pH= 7.4, 10 mM), followed by the addition of 20 μL 
DMSO solution of SYTO®RNASelect™ marker (0.2 μM). The fluorescence emission of the 
mixture was measured by FluoroMax-2 fluorimeter (λex= 450 nm).  
Influence of PAP-LP-MSN on the expression of enhanced green fluorescence protein 
(EGFP) in HeLa cells. Modified from our previously reported procedure[1], 0.5 μg of a 
plasmid DNA (pEGFP-C1) that is encoding for an enhanced green fluorescence protein 
(Clontech) was added to a 100 μL suspension of G4-PAMAM-MSN (10 μg) that was 
prepared by dispersing MSN (1.0 mg) and G4-PAMAM (0.13 mL) in 1.0 mL of PBS (10 
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mM, pH 7.4) for 8 h at 25 °C.  The mixture was stirred for 4h at 4 °C.  From this mixture, 36 
μL of the suspension were added to HeLa cells cultured on 48-well plates.  HeLa cells were 
seeded at the density of 5 × 104 cells per well in 500 μL D-10 medium.  After incubation for 
24 h, the D-10 medium was replaced by 500 μL of a DMEM solution containing the 
transfection agent. After 2 h of incubation with the transfection agent at 37 °C, the mixture 
containing residual pEGFP DNA vector and G4-PAMAM-MSN complex was removed by 
washing the transfected cells with PBS buffer. The medium was replaced by 500 μL of PAP-
LP-MSN (40 μg/mL) in the D-10 medium for 8 h. The suspension of PAP-LP-MSN was then 
removed and the wells were washed with PBS buffer, followed by adding 500 μL of the D-10 
medium to the wells. The culture was continued for another 24 h to allow the incorporation 
of gene.  The expression of pEGFP was monitored by using a LEICA DMIRE2 fluorescent 
microscope.  
Measurement of the internalization of PAP-LP-MSN and AP-PAP-MSN in HeLa cells 
by flow cytometry. HeLa cells were seeded at the density of 5 × 104 cells per well in six-
well plates in 3 mL D-10 medium with coverslips at the bottom of the wells.  After 
incubation for 48 h, the D-10 medium was replaced by 3 mL of PAP-LP-MSN or AP-PAP-
MSN suspensions at concentrations 1, 10, 25, 50, and 100 μg/mL) in the serum-free DMEM 
medium for 12 h. All the tests were run in triplicate. The cells were washed with medium and 
harvested by trypsinization. After centrifugation, the cells pellets were re-suspended in 
DMEM medium, and analyzed by flow cytometry with a Becton-Dickinson FACSCanto 
cytometer and DB-FACS Diva software. To distinguish the true fluorescence generated by 
the loaded MSN from the natural auto-fluorescence of cells, a threshold of fluorescence 
intensity was established by performing the flow cytometry analysis on HeLa cells incubated 
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without any PAP-LP-MSN or AP-PAP-MSN. The threshold was set at an intensity of 
fluorescence slightly above the highest value observed for control samples (HeLa cells only). 
The number of cells with endocytosed PAP-LP-MSN or AP-PAP-MSN was determined by 
counting the cells showing fluorescence intensity higher than the threshold. 
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Table S1. Structural Properties of MSN materials 
 
 
Sample 
BET 
Surface 
Area (m2/g) 
BET 
Pore Volume 
(mL/g) 
BJH 
Pore Diameter 
(Å) 
Zeta-Potential 
(mV) 
Particle size 
DLS (nm) 
PAP-LP-MSN 705 1.034 57 1.3 ± 0.4 200 ± 40 
AP-PAP-MSN 669 0.684 25 10.5 ± 1.5 320 ± 35 
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Figure captions 
Figure S1. Powder X-ray diffraction patterns. (a) PAP-LP-MSN, and (b) AP-PAP-MSN. The 
two materials exhibited hexagonal type mesoporous structure characteristic of MCM-41. 
Figure S2. N2 sorption isotherms of PAP-LP-MSN. (a) BET nitrogen sorption isotherms, and 
(b) BJH pore size distribution. 
Figure S3. N2 sorption isotherms of AP-PAP-MSN. (a) BET nitrogen sorption isotherms, 
and (b) BJH pore size distribution. 
Figure S4. (a) Solid state 13C CP-MAS NMR spectra of PAP-LP-MSN, and (b) Solid state 
29Si CP-MAS NMR spectra of PAP-LP-MSN. 
Figure S5. Confocal fluorescence images of HeLa cells (a-c), and HeLa cells loaded with 
MSN (d-f), and LP-MSN (g-i) in presence of SYTO®RNASelect™. (a, d, and g) Phase 
constrast of cells, (b, e, and h) SYTO®RNASelect™ stained cells, and (c, f, and i) red 
fluorescence of the endocytosed of MSN and LP-MSN. 
Figure S6. Fluorescence emission spectra of PAP-LP-MSN (blue line) and PAP-LP-MSN 
with yeast tRNA (red line).  (Excitation wavelength = 450 nm) 
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Figure S5 
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Figure S6 
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Scheme Captions 
Scheme S1.  Synthesis of aminopropyl-MSN (AP-MSN).  Aminopropyltrimethoxysilane was 
first grafted to the cetyltrimethylammonium bromide (CTAB)-containing MSN in dry 
toluene. The CTAB surfactant template was removed under an acidic condition to afford AP-
MSN. 
Scheme S2.  Synthesis of N-[3[(3,8-diamino-6-phenyl-5-phenanthridium)propyl]-3-
aminopropyl-functionalized, MCM-41 type mesoporous silica nanoparticle materials (PAP-
LP-MSN). 
Scheme S3. Synthesis of aminopropyl-PAP-MSN (AP-PAP-MSN). 
Aminopropyltrimethoxysilane was first grafted to the cetyltrimethylammonium bromide 
(CTAB)-containing MSN in dry toluene. The CTAB surfactant template was removed under 
an acidic condition to afford AP-MSN. PAP-TMS was then grafted to the interior surface of 
AP-MSN in dry toluene to yield AP-PAP-MSN. 
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Scheme S2 
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Scheme S3 
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CHAPTER 6. GENERAL CONCLUSIONS 
 The continuous advanced on the design and synthesis of therapeutic drugs for various 
diseases is improving our everyday life. In addition, new therapeutic strategies are currently 
being developed such as gene and protein therapy, which would change the current way 
human disease is treated. However; in some cases, such as chemotherapy for cancer where 
the use of toxic drugs results in acute and chronic side effects; or gene therapy where the 
precious cargo has to be protected from the harsh environment of the human body, the use of 
a vehicle that could transport and release these drugs/genes to the desired site is required. To 
circumvent these problems different delivery systems have been developed and others are 
under investigation such as polymers, liposomes, dendrimers, and inorganic nanoparticles. 
Prof. Dr. Victor Shang-Yi Lin and his group have contributed to this field developing 
mesoporous silica nanoparticles (MSNs) as a potential platform for drug delivery. Their 
results have demonstrated that high amount of drugs or bio-imaging molecules can be loaded, 
transported, and released in a controlled fashion by MSNs. The research presented in this 
dissertation provides novel strategies for the controlled release of guest molecules and for 
manipulating intracellular processes through the interaction of functionalized MSNs with 
bioactive molecules. 
 The design of site-specific stimuli-responsive drug delivery systems is of utmost 
importance for the continued advancement of the pharmaceutical industry. So far, different 
stimuli-responsive systems based on MSNs have been developed where the release of the 
cargo is triggered by internal stimuli such as change in pH, reducing environment, and 
enzymatic activity. However, very few delivery MSN carriers that work under biological 
conditions were found in the literature where the release of the guest molecule is controlled 
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by external stimuli (radiation, ultrasound, and magnetic field). The ability of manipulating 
the delivery of drugs using an external trigger could result in an accurate control of the time 
and site of release. In this study we proposed to develop a MSNs-based drug delivery vehicle 
where the release of the guest molecule could be trigger by irradiation under biocompatible 
conditions. This work took advantage of the synergy between two of the most used inorganic 
nanoparticles for biomedical applications, gold nanoparticles and MSNs. This irradiation-
triggered system was design based on the electrostatic interaction between a gold 
nanoparticle bearing a positively charged photo-responsive linker and MSN. It was found 
that under mild irradiation conditions the release of fluorescein and the anticancer drug 
paclitaxel in solution and in human cells, respectively, can be accomplished. Moreover, this 
work demonstrated that the MSNs carrier exhibited zero premature release in absence of 
irradiation. For in vivo applications the scope of this research can be expanded developing 
MSNs systems that respond to irradiation with deeper penetration such as near-infrared.  
 The versatility of MSNs as delivery vehicle was demonstrated in this work. Besides 
drugs and bio-imaging agents, other biogenic molecules can be loaded to MSN and 
efficiently transported inside the cells. This concept was demonstrated in this study by using 
cysteine as cargo. This peptide is essential for the intracellular synthesis of glutathione, 
which has a direct impact in controlling the homeostasis of cells. The cysteine molecule was 
chemically attached to MSNs by a labile disulfide bond, which is broken by intracellular 
reducing agents. It was found that due to their high loading capacity, efficient internalization, 
and effective endosomal escape, MSNs can successfully release cysteine. This was further 
demonstrated by comparing the delivery performance of MSNs against a conventional 
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cysteine pro-drug, N-acetylcysteine. It was found that the efficiency of the MSN vehicle is 
almost 400 times better than N-acetylcysteine.  
   In addition to the application of MSNs as drug delivery vehicles, one of the potential 
areas of research for these nanomaterials is the possibility of manipulating various 
intracellular processes through their interaction with bioactive molecules, proteins, 
oligonucleotides, and/or organelles. To prove this idea, an oligonucleotide intercalating 
molecule was attached to the exterior particle and interior pore surface of MSNs. It was 
demonstrated by confocal microscopy that the MSNs that contain the intercalating molecule 
in the exterior surface bind to cytoplasmic oligonucleotides. Moreover, it was found that this 
interaction results in a sever inhibition of the cell growth. In contrast, the same intercalator 
group attached to the interior pore of MSNs did not exhibit any interaction with intracellular 
oligonucleotides. It was shown by using an extraneous plasmid DNA that is encoding for an 
enhanced green fluorescence protein that the intracellular interaction of the MSNs bearing 
the intercalator group on the external surface inhibited the expression of the protein. This 
work demonstrated that taking advantage of the structural and chemical features of MSNs it 
is possible to design nanodevices that can manipulate intracellular processes.    
 The work presented in this dissertation opens the door for the design of new 
generations of stimuli-responsive delivery MSNs systems based on external stimuli. In 
addition, new applications for the manipulation of intracellular processes can be envisioned, 
such as the selective interaction of MSNs with intracellular enzymes, and organelles. Further 
work is required to translate all these exciting findings to in vivo applications. For instance, 
the biocompatibility, biodistribution, and biodegradability in vivo of all these systems need to 
be evaluated.   
